

1 UNITED STATES NUCLEAR REGULATORY COMMISSION

2 BRIEFING ON STATUS OF IMPLEMENTATION

3 OF ENERGY POLICY ACT OF 2005

4 + + + + +

5 MONDAY, MAY 15, 2006

6 1:00pm – 3:30pm

7 + + + + +

8 NUCLEAR REGULATORY COMMISSION:

9 NILS J. DIAZ, CHAIRMAN

10 EDWARD MCGAFFIGAN, JR., COMMISSIONER

11 JEFFREY S. MERRIFIELD, COMMISSIONER

12 GREGORY B. JACZKO, COMMISSIONER

13 PETER B. LYONS, COMMISSIONER

14 PANEL 1:

15 LUIS A. REYES, EDO

16 STEVE O’CONNOR, SENIOR OPERATIONS

17 ASSISTANT, EDO

18 SCOTT MOORE, CHIEF,

19 RULEMAKING & GUIDANCE BRANCH, IMNS

20 KATHLEEN SCHNEIDER,

21 SENIOR HEALTH PHYSICIST, OSTP

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

~~GARMON WEST, CHIEF, NSIR~~

PANEL 2:

PEARCE O'KELLEY, CHAIR, CRCPD

JARED W. THOMPSON, PAST-CHAIR, OAS

PANEL 2 (CONT'D):

SALLY W. SCHWARTZ, NUCLEAR PHARMACIST,

ACMUI MEMBER

ROY W. BROWN, SENIOR DIRECTOR,

FEDERAL AFFAIRS, CORAR

ALSO PRESENT:

JANET SCHLUETER, STP

KAREN CYR, OGC

CHARLIE MILLER, NMSS

TRISH HOLAHAN, NMSS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

C-O-N-T-E-N-T-S

Introduction by Chairman Diaz	4
Panel 1:	
Presentation by Mr. Strosnider	8
Presentation by Mr. O’Connor	9
Presentation by Mr. Moore	12
Panel 2:	
Presentation by Mr. Thompson	67
Presentation by Mr. O’Kelley	75
Presentation by Dr. Schwarz	78
Presentation by Mr. Brown	88
Presentation by Dr. Miller	107
Adjourned	121

~~P-R-O-C-E-E-D-I-N-G-S~~

1:00 p.m.

CHAIRMAN DIAZ: Good afternoon. I think we're missing the EDO. This is a unique opportunity.

(Laughter.)

CHAIRMAN DIAZ: We should go ahead with a series of management issues very quickly.

COMMISSIONER MCGAFFIGAN: I would point out, this meeting wasn't supposed to start until 1:00 -- this part.

CHAIRMAN DIAZ: That is true.

MS. VIETTI-COOK: Yes, this is --

COMMISSIONER MERRIFIELD: Well, just in time doesn't apply to Commission meetings, so --

(Laughter.)

CHAIRMAN DIAZ: Well, shall we --

COMMISSIONER MCGAFFIGAN: Who is the next ranking person?

CHAIRMAN DIAZ: That's okay. I can entertain us for the next two or three minutes. There's no problem with that. Normally, I'm at a loss for words, but on this occasion, I can find a few words.

So, anyhow, the Commission going to meet with the staff,

1 ~~with its representatives of the Organization of Agreement States, the~~  
2 medical industry, and the Advisory Committee on the Medical Use of  
3 Isotopes, to discuss the progress on implementing the requirements that  
4 were set forth in the Policy Act of 2006.

5           Now, as you know, the Policy Act of 2006 created many  
6 challenges for many, many agencies, and one of those agencies where  
7 challenges were very present is the NRC. I think the staff has been  
8 working for quite a bit of time, and the Commission has been kept aware  
9 of where we're going with those issues.

10           In some, we seem to be progressing quite well. In others,  
11 we're having difficulties of the timing and implementation. I believe that  
12 what we are looking for today is a clear understanding of where we  
13 stand. We want to hear from the stakeholders that are visiting with us  
14 today in what they see on their side of the issue. The Commission, I'm  
15 sure, has different and varied opinions on the subject. That will raise  
16 some questions. I would like to point out that Commissioner McGaffigan  
17 has been keeping track of these issues very closely, and by pure chance,  
18 he's going to go first today. So he's going to be using a little bit of his  
19 time.

20           COMMISSIONER MCGAFFIGAN: I will still promise to ask  
21 questions the last five seconds of my time in order to extend my time.

1 CHAIRMAN DIAZ: We can note that.

2 COMMISSIONER MCGAFFIGAN: Typical Commission  
3 practice.

4 CHAIRMAN DIAZ: Would you please make a note of that,  
5 Madam Secretary: that Commissioner McGaffigan is going to take some  
6 time to ask questions, besides making some comments.

7 I think that being that it is 1 o'clock, we can go ahead and  
8 proceed. Oh, I'm sorry...

9 COMMISSIONER MCGAFFIGAN: Mr. Chairman, I think we  
10 can filibuster a little longer for Luis. I just wanted to join you in  
11 welcoming folks. We're going to focus today on areas where we're  
12 having a little bit of difficulty in implementing EAct, but we have done a  
13 heck of a lot in terms of implementing the provisions of the Energy Policy  
14 Act of 2005. We're well ahead of the game, compared to, I think, our  
15 sister agency at the Department of Energy.

16 On the other hand, we have perhaps fewer provisions, but a  
17 much higher percentage of our provisions have rule language associated  
18 with them, and we're well along with the rulemakings. So I commend the  
19 staff for that. We only get laws passed about once every 13 years, that  
20 affect us – 1992 being the previous case. And I know our staff wants to  
21 be the A student when it comes to doing everything necessary to

1 implement the law.

2 COMMISSIONER MERRIFIELD: Mr. Chairman, I would only  
3 join Commissioner McGaffigan in recognizing a significant amount of  
4 work in progress by our staff and want to compliment them for their  
5 commitment to that duty of time limits. And certainly, Mr. Chairman, I  
6 know we've got some issues we'll be discussing today, but hopefully that  
7 will give us an opportunity to focus a bit more and come to resolution so  
8 we can meet those timelines.

9 CHAIRMAN DIAZ: He's growing a mustache.

10 (Laughter.)

11 COMMISSIONER MCGAFFIGAN: We gave him time.

12 (Laughter.)

13 CHAIRMAN DIAZ: We've got to be careful.

14 COMMISSIONER MCGAFFIGAN: I – I'm sorry.

15 COMMISSIONER JACZKO: I don't have anything at this  
16 point.

17 CHAIRMAN DIAZ: With that, the new version of Mr. Reyes.

18 (Laughter.)

19 PRESENTATION BY MR. STROSNIDER

20 MR. STROSNIDER: At the risk of seeming presumptuous,  
21 I'll deliver his message. Actually, I'm acting for Marty today. So if this is

1 ~~wrong protocol, you can talk to Marty, I guess.~~

2 Good morning, or good afternoon, Commissioners. Sorry.

3 The staff and stakeholders are here today to update the Commission on  
4 activities that are being conducted under the Energy Policy Act of 2005.

5 We have made a number of accomplishments as an agency in a short  
6 time since the Energy Policy Act was passed by Congress and signed  
7 into law by the President nine months ago.

8 This afternoon, the staff will brief you on the status of those  
9 activities, with a focus on three sections of the Act that require  
10 rulemaking. The Energy Policy Act expanded NRC's authority  
11 significantly, such as regulation of NARM and fingerprinting for access to  
12 materials. And the staff is working diligently to implement those portions  
13 of the Act.

14 Following the staff's presentation and the Commission's  
15 questions, a second panel of stakeholders, including representatives  
16 from the Organization of Agreement States, the Conference of Radiation  
17 Control Program Directors, and the Council on Radionuclides and  
18 Radiopharmaceuticals, and the NRC's Advisory Committee on the  
19 Medical Uses of Isotopes will bring their perspectives to the table. And  
20 I'm going to say, we really appreciate their participation today.

21 Now, I'm joined in this briefing by Steve O'Connor, currently



1 ~~-serving a rotation in the EDO's office as a Senior Operations Assistant;~~  
2 and Scott Moore, our Chief of the Rulemaking and Guidance Branch in  
3 NMSS. Also at the table are Kathleen Schneider, Senior Project  
4 Manager in the Office of State and Tribal Programs; and Garmon West,  
5 Chief of the Licensing Personnel Security Branch in the Office of Nuclear  
6 Security and Incident Response.

7 With that, I'm going to turn it over to Steve.

8 PRESENTATION BY MR. O'CONNOR

9 MR. O'CONNOR: Thanks, Jack. Good afternoon, Chairman,  
10 Commissioners. I'm going to provide a brief overview of the staff's  
11 activities to date in implementing the Act by starting with our  
12 accomplishments.

13 I'd like to point out, though we've completed many of the  
14 NRC's actions mandated in the Act, the status of the significant  
15 implementation milestones are shown in the table provided in the  
16 background materials.

17 We've modified the table to be used as a handout for the  
18 audience today by eliminating the milestone dates. My overview is not  
19 intended to provide a detailed status of the staff's activities. That detail  
20 has been provided to you in a Commission paper dated May 4<sup>th</sup>, and it is  
21 also included in the background material. This overview is more of an

1 ~~overall status of our implementation activities.~~

2           The table in your background material summarizes  
3 significant agency actions required for implementation of the Act. As  
4 you'll see the staff has completed more than a third of the overall actions  
5 and is well on the way to completing the majority of the remaining  
6 actions. A TBD is shown on three sections where we're awaiting input  
7 from another agency, such as the Department of Energy, or the  
8 Department of State.

9           The staff has completed all actions related to certain  
10 sections of the Act by issuing final rules amending the regulations  
11 related to Sections 601 through 609 of the revised Price-Anderson Act,  
12 Section 625 for the elimination of antitrust reviews, Section 630 for  
13 revised export licensing criteria, and one portion of Section 651(d)(1)  
14 related to additional controls on the import and export of radioactive  
15 materials.

16           We've also cleared all actions related to Section 651(a)(3),  
17 for assigning Federal security coordinators to each region, Section  
18 651(b) for requiring backup power for certain emergency notification  
19 systems, and Section 651(c)(3) for promulgating provisions to cover  
20 travel expenses for certain individuals who either are assisting NRC or  
21 employed by the NRC.



1 ~~to focus on three portions of the Energy Policy Act that are in progress:~~

2 Section 651(e), on amending the definition of byproduct material,  
3 otherwise known as the NARM rulemaking; Section 656, on secure  
4 transfer of nuclear materials; and Section 652, on fingerprinting and  
5 criminal history records check.

6 The Energy Policy Act amended the definition of byproduct  
7 material to include three new groups of radioactive materials highlighted  
8 here. The staff has developed a draft proposed rule that is with the  
9 Commission in SECY-06-0069. This NARM rulemaking will be the first  
10 area that we focus on today.

11 The Act requires the NRC to define the term “discrete  
12 source” which applies to the radium-226 and NORM materials that pose  
13 a threat similar to the threat posed by discrete sources of radium-226.  
14 The term “discrete source” doesn’t apply to accelerator-produced  
15 radioactive materials.

16 The staff consulted with other agencies in developing the  
17 draft proposed rule. And in our view, and the views of other agency  
18 representatives, nothing was identified that poses a threat similar to the  
19 threat posed by a discrete source of radium-226. So, for the purposes of  
20 the draft proposed rule, this is just a placeholder. No such materials  
21 known at this time.

1 ~~Finally, the Act gives NRC authority over material produced~~  
2 for use for a commercial, medical, or research activity. It covers material  
3 in these three categories produced before, on, or after the date of the  
4 Act.

5           Could I have the next slide, please?

6           Because the Energy Policy Act was immediately effective  
7 and gave NRC authority in an area previously regulated by the States,  
8 Congress created a provision for the Commission to grant waivers. This  
9 provision allows current programs to continue regulating and individuals  
10 to continue using NARM materials while NRC develops a regulatory  
11 framework and infrastructure. NRC issued a waiver on August 25<sup>th</sup>, last  
12 year; less than three weeks after the Energy Policy Act was signed into  
13 law. And the waiver was published in the Federal Register on August  
14 31<sup>st</sup>.

15           The waiver provides time for an orderly transition to NRC  
16 authority in this area, continuing regulatory oversight and protecting  
17 public health and safety at the same level as before the Act, while NRC  
18 develops its final regulations and licensing and inspection program.

19           Can I have the next slide, please?

20           Section 651(e) requires NRC to issue final regulations by  
21 February 7, 2007. The Energy Policy Act's language specifically

1 ~~requires NRC to “consult with states and other stakeholders.”~~ The Act  
2 also requires the Commission, to the maximum extent practicable, to  
3 cooperate with States and use model State standards.

4           The Conference of Radiation Control Program Directors,  
5 CRCPD, publishes suggested State regs for control of radiation, also  
6 known as SSR’s. The staff reviewed the SSR’s and State requirements  
7 and found that most Agreement States have adopted the SSR’s or  
8 requirements similar to the SSR’s, although not always verbatim. Non-  
9 Agreement States use the SSR’s to varying degrees.

10           In developing the draft proposed rule, the staff used the  
11 SSR’s to the maximum extent practicable and adopted an approach  
12 similar to the States by putting the requirements for NARM radionuclides  
13 throughout the existing regulations and 10 CFR, rather than creating a  
14 new special section of the regulations for these materials.

15           Could I have slide number 7 please?

16           While developing the draft proposed rule, the staff  
17 conducted a number of outreach activities with states and stakeholders  
18 within the time constraints imposed by the Energy Policy Act for the final  
19 rule.

20           We held a public meeting with a roundtable discussion  
21 format on November 9 here at headquarters to solicit input. That

1 ~~roundtable discussion helped our rule writers because it was held early~~  
2 and included a number of different viewpoints at the table, and it helped  
3 shape the proposed rule.

4           Also, last November, we held an interagency meeting with  
5 representatives from other Federal agencies to discuss the definition of  
6 discrete source. Included at that meeting were the Department of  
7 Transportation, the Department of Energy, including the National Nuclear  
8 Security Administration, the Department of Defense, the Department of  
9 Commerce, the Department of Homeland Security, and the  
10 Environmental Protection Agency.

11           Could I have the next slide, please?

12           The NARM rulemaking has involved states to an  
13 unprecedented degree, and we have consulted and cooperated with both  
14 Agreement and non-Agreement States. Shown here are examples of  
15 how states have been involved in the 651(e) rulemaking.

16           Four States -- Florida, Michigan, Oregon, and Texas --  
17 served on the Rulemaking Working Group in the development and writing  
18 of the rule. Two States, Arkansas and California, had representatives on  
19 the Steering Committee, representing OAS and CRCPD respectively.

20           Because of the rapid timing of the rule and other  
21 implementation issues, the Steering Committee met frequently, nearly

1 ~~every week between mid-January and March. Two States, Oregon and~~

2 North Carolina, participated in the NMSS EAct Task Force. That was a  
3 separate unit that we created within NMSS to address many of the  
4 Energy Policy Act requirements.

5           The Oregon representative's involvement was notable. That  
6 was Martha Dibblee – in that NRC, CRCPD, and Oregon arranged for her  
7 to come work here out of Two White Flint for six months. The  
8 arrangement provided staff with immediate access to a State rep's views  
9 and assistance.

10           Two States, California and Illinois, had representatives who  
11 provided assistance as needed to members of our Working Group and/or  
12 Steering Committee.

13           The level of State involvement and coordination on this rule  
14 has been unmatched in recent memory, and we're indebted to the States  
15 for their insight, their expertise, and dedication to this effort.

16           Finally, as shown on the next slide, the staff made a number  
17 of presentations to organizations, including OAS, CRCPD, CORAR, and  
18 ACMUI, all of whom you're going to hear from on the next panel.

19           Here is a list of the meetings at which we made  
20 presentations or held discussions. The staff balanced requests from  
21 stakeholders for additional public meetings with the need to issue the



1 ~~proposed and final rules on time, considering that the same staff would~~  
2 be working on both outreach efforts and the rulemaking.

3 In correspondence and in SECY-06-0069, the staff has  
4 committed to holding at least one public meeting during the public  
5 comment period on the proposed rule.

6 COMMISSIONER MERRIFIELD: Scott, these all have a tune  
7 of familiarity to them, but the High Country Nuclear Medicine  
8 Conference: what does that refer to?

9 MR. MOORE: It is a nuclear medicine conference arranged  
10 by CORAR, and we were invited by CORAR to speak at it. We made a  
11 presentation at it. Actually, I would like to recognize Lydia Chang. Lydia  
12 Chang, the team leader for the group that wrote the SECY paper, went to  
13 the nuclear medicine conference and made the presentation there on the  
14 proposed rule.

15 On slide number 10, the current status of the NARM  
16 rulemaking under Section 651(e) is that a proposed rule is developed  
17 and is with the Commission. As of April 7, the draft proposed rule and  
18 SECY paper were made publicly available on the NRC's website.

19 The Energy Policy Act requires the Commission to issue final  
20 regulations, establishing the definition of byproduct material, not later  
21 than 18 months after the enactment; that is, February 7, 2007.

1 ~~This date is aggressive, since normal notice and comment~~  
2 rulemaking takes longer, and this is one of the most significant rules that  
3 we've developed. Currently, we're behind our original schedule which  
4 forecasts publication of the proposed rule by the end of April. We expect  
5 to make that up during the final rule phase, but it's going to be a  
6 challenge to make the February date.

7 Could I have the key issues slide please?

8 The Commission paper and the draft proposed rule and the  
9 SECY paper address a number of key issues on the NARM rulemaking.  
10 This slide touches on a few of them.

11 The definition of "discrete source" is central to the amount  
12 and type of radium-226 that NRC regulates. After consulting with other  
13 agencies and working with the States, the staff is proposing a definition  
14 that includes the concepts of a source with physical boundaries,  
15 separate and distinct from the radiation present in nature, which the  
16 radionuclide concentration has been increased by human processes, and  
17 with the intent that the concentrated radioactive material will be used for  
18 its radiological properties. Other radium-226, such as pipe scale that's  
19 not regulated by NRC, will continue to be regulated by States.

20 Another key issue is the degree to which NRC should  
21 regulate radioactive material incidentally produced in an accelerator.

1 ~~Staff quickly learned that accelerators have both intentionally produced~~  
2 radioactive material -- that's the target material -- and incidentally  
3 produced radioactive material from activation.

4           In the draft proposed rule, we propose regulating the  
5 radioactive material both intentionally and incidentally produced in  
6 accelerators that are operated to produce a radioactive material for use  
7 for commercial, medical, or research activity. That is, if the accelerators  
8 are operated to intentionally produce radioactive material, such as a PET  
9 production facility, then both types of radioactive material would be  
10 included. We do not propose to include other types of accelerators, such  
11 as medical LINACS used to treat patients.

12           The staff wrestled with the issue of how to regulate certain  
13 discrete sources of radium-226, especially older consumer products, like  
14 radium watch hands and antiques.

15           While the staff would have preferred to establish an  
16 exemption for such products -- and there are apparently a lot of them in  
17 circulation still -- we don't have a sufficient technical basis to support an  
18 exemption. Without that specific information, we are proposing a graded  
19 approach, recommending a general license for certain items containing  
20 radium-226.

21           Finally, the strategy for implementing the final rule and

1 ~~terminating the waiver is fairly complex. The waiver currently runs~~  
2 through August 7, 2009. We do not want every possessor of accelerator-  
3 produced material and discrete sources of radium-226 in each non-  
4 Agreement State to submit an application for license on that day because  
5 the applicants may be in immediate noncompliance on the very following  
6 day.

7           So we are working with our OAS and CRCPD reps on the  
8 Steering Committee to develop a transition plan. We plan to terminate  
9 the waivers in groups or in batches, allowing possessors time to file  
10 amendments and applications.

11           Could I have slide number 12, please?

12           Another key issue during the rule development was  
13 compatibility of the definition of byproduct material. To put this into  
14 context, there are numerous sections of the draft proposed rule that  
15 require compatibility determinations. A table in the draft Federal  
16 Register notice shows well more than 50 revised or new sections with  
17 compatibility determinations.

18           We followed the process described in Management Directive  
19 5.9, Adequacy and Compatibility of Agreement State Programs, in  
20 determining the correct level for the definition of byproduct material. In  
21 particular, Handbook 5.9, Part 3, is a series of questions that the

1 ~~reviewer is supposed to ask in making a finding.~~

2 For the definition of byproduct material, the staff  
3 recommended the designation of H&S, health and safety. A designation  
4 of H&S is actually an adequacy designation; it's not a compatibility  
5 criteria. One goes through the compatibility questions and then asks the  
6 final question about whether the absence of the essential objectives  
7 could create a situation that could directly result in an exposure in  
8 excess of the limits. If the answer to that question is yes, then the  
9 program element is not required for compatibility, but it is identified as  
10 having a particular health and safety significance. Agreement State  
11 programs are required to address H&S designated items, and then NRC  
12 staff reviews them.

13 Could I have slide number 13, please?

14 Agreement States did not agree with staff's conclusion  
15 generally that the definition of byproduct material and the definition of  
16 discrete source as well should be designated H&S. In particular, State  
17 members of the Steering Committee representing OAS and CRCPD  
18 disagreed with the designation of H&S for byproduct material, noting that  
19 it would require statutory changes in some States.

20 OAS and CRCPD wrote to NRC expressing disagreement  
21 with the staff's designation of H&S for the definition of byproduct

1 ~~material. In the spirit of full disclosure, we've attached the letters from~~  
2 OAS and CRCPD to the Commission paper in their own words, rather  
3 than paraphrasing them for you, so you could see what OAS and CRCPD  
4 said.

5           The States would strongly prefer a compatibility category D  
6 for the definition of byproduct material. However, the staff notes, in the  
7 third bullet on this slide, that a compatibility category D program element  
8 isn't reviewed by NRC staff, either in house or during IMPEP, because  
9 they are not a required part of an agreement program.

10           The next slide provides a quote from the Commission paper,  
11 SECY-06-0069, Enclosure 5, which sums up the staff's conclusion on  
12 why the definition of byproduct material should be designated H&S.

13           If the definition of the term "byproduct material" or some  
14 other term, such as "radioactive material" that encompasses all of the  
15 byproduct material was not somewhere within the State program, then  
16 it's possible that some byproduct material could escape oversight and  
17 result in an overexposure to an individual in excess of the Part 20 limits.

18  
19           We wouldn't have a problem if the State used a term such as  
20 "radioactive material" throughout its regulations and that term  
21 encompassed the new forms of the byproducts material. However, we

1 ~~found that there are differences in terminology within individual State~~  
2 regulations. For example, States that use both the terms “radioactive  
3 material” and “byproduct material.” A designation of H&S would require  
4 States to assess their own programs to see if changes or updates are  
5 needed, if at all.

6           Could I have slide 15, please?

7           So to summarize where we are on the NARM rulemaking:  
8 We have developed a draft proposed rule that included stakeholder  
9 outreach and State involvement in a very short time period. The draft  
10 proposed rule addresses a key Energy Policy Act issue, namely, the  
11 expansion of NRC’s authority to cover NARM and discreet sources of  
12 radium-226.

13           In developing the draft proposed rule, staff tackled a number  
14 of tough policy issues.

15           Next slide, please.

16           We will continue outreach activities after the proposed rule is  
17 published, holding at least one public meeting and continuing to interact  
18 with Agreement States, non-Agreement States, the public, and affected  
19 industry.

20           Finally, achieving the February 7, 2007 due date for the final  
21 rule will be a challenge. We must continue at a very fast pace to meet

1 ~~the statutory deadline.~~

2 Our second topic on the next slide is Section 656 on secure  
3 transfer of nuclear materials. The Energy Policy Act requires that for  
4 materials transferred or received pursuant to an import or export license,  
5 the Commission shall establish a system such that that materials are  
6 accompanied by manifests and that each individual receiving or  
7 accompanying the transfer shall be subject to a “security background  
8 check conducted by appropriate Federal entities.”

9 Next slide, please.

10 The statute requires that the Commission issue regulations  
11 not later than a year after the date of enactment of the Act; that’s August  
12 8 of this year, and from time to time thereafter, as it considers  
13 necessary, identifying radioactive materials or classes of individuals that  
14 are appropriate exceptions to these requirements.

15 Although the regulations must be issued within a year, the  
16 statute allows the background check requirement to become effective on  
17 a date established by the Commission.

18 Next slide, please.

19 Currently, we're developing a proposed rule on Section 656.  
20 We drafted an initial version of the proposed rule and provided it to the  
21 Agreement States and NRC offices for review and comment. We’re also



1 ~~coordinating with the DOT, the Transportation Security Administration,~~  
2 and the U.S. Coast Guard.

3 The initial version of the proposed rule had been crafted to  
4 rely heavily on existing background check requirements and other  
5 agency's regulations. As with many of the rulemaking activities in the  
6 Energy Policy Act, this action has an aggressive schedule. The draft  
7 proposed rule is due to the Commission in June.

8 The statute requirements for a system of manifests are not a  
9 problem. There are already existing DOT and NRC requirements for  
10 shipping papers that already require this information. The statute  
11 requirements for a system of security background checks have proven to  
12 be a lot more difficult.

13 The particular issue is that Section 652 on fingerprinting and  
14 criminal history background checks, which I'll discuss last, is broader  
15 than Section 656. Sequentially, it would make more sense for to us  
16 complete the requirements for the more comprehensive Section 652  
17 rulemaking first.

18 Slide number 20 please.

19 In their review of the draft proposed rule, Agreement States  
20 and DOT raised some concerns. Some Agreement States note that  
21 Section 656 ties the system of security background checks to an import

1 ~~or export license. They note that NRC alone has authority to issue~~  
2 import and export licenses, and they suggest that these requirements  
3 should be placed by NRC on the importer, not by the Agreement States  
4 on the possession licensee.

5 DOT agreed with our findings that manifest requirements are  
6 not a problem, but they raised issues about it's staff's overly broad  
7 definition of "accompanying".

8 We note that establishing exceptions now for Section 656  
9 rulemaking may set a precedent for the more comprehensive Section 652  
10 rulemaking on fingerprinting and criminal history records checks. And,  
11 finally, the staff is cautious about opening Part 110 to establish  
12 requirements of this nature on importers. We have not used Part 110 in  
13 this manner in the past, so it would be a departure from past practice  
14 with regard to importers.

15 Could I have the next slide, please?

16 In response to stakeholder comments, we're drafting a  
17 proposed rule that provides exceptions for material other than the most  
18 risk-significant quantities. Rather than establishing a system of  
19 background checks now in the Section 656 rule, we would address  
20 fingerprinting for the most risk-significant licensees through orders until  
21 the broader Section 652 rulemaking can be completed.

1           ~~The immediate 656 rule would just address the exceptions,~~  
2           as we are crafting it now. The rest of the security background check  
3           system would be handled through orders until Section 652 could be put  
4           in place through rulemaking. Staff would clearly indicate in the  
5           Statement of Considerations for the Section 656 proposed rule that we  
6           will revisit the exceptions when the Commission finalizes its broader  
7           fingerprinting and criminal history record check rules, such as Section  
8           652.

9                         Next slide, please.

10                        Our next steps are to complete the draft proposed rule, as I  
11           just described, and send it to the Commission in June. We are also  
12           drafting a letter to inform Congress that we will likely not meet the  
13           August 7th due date for a final rule. Although this approach may allow to  
14           us come closer to the due date, we still expect the notice and comment  
15           rulemaking will take until fall of this year to finalize the rule on Section  
16           656.

17                        We are reaching out to Agreement States, DOT, TSA, and  
18           the Coast Guard, and are going to continue to do so. Wherever possible,  
19           for persons receiving and accompanying the material, we are trying to  
20           reference or point to other agencies' requirements and tier off of those,  
21           and that would be done in the orders now.

1           ~~The staff will send out orders to require fingerprinting and~~  
2 criminal history records checks for unescorted access to material to  
3 applicable licensees with higher-risk sources. That addresses for those  
4 licensees the statute's requirement that the Commission establish a  
5 system to require security background checks for individuals receiving or  
6 accompanying the material.

7           Finally, the staff plans to address the broad issue of  
8 fingerprinting and criminal history record checks in the more  
9 comprehensive Section 652 rulemaking, which brings us to our last focus  
10 area on the next slide.

11           Section 652, fingerprinting and criminal history records  
12 checks. This slide shows the key requirements of Section 652. The  
13 statute has two key aspects requiring fingerprinting: unescorted access  
14 to radioactive material that the Commission determines to be of such  
15 significance, and next, access to safeguards information.

16           Could I have the next slide?

17           The law also requires the fingerprints to be submitted to the  
18 U.S. Attorney General for identification and criminal history records  
19 checks.

20           Next slide, please.

21           The statute requirements for access to safeguards

1 ~~information became effective on the date that the law was enacted last~~

2 August because the law didn't grant the Commission discretion on who it  
3 applied to in the same manner as it did with access to materials. And  
4 because it covers any individual, everyone who has access to safeguards  
5 information must now be fingerprinted or be exempted by rule.

6 The staff is rapidly developing orders to those licensees,  
7 other than power reactors, who have or will receive safeguards  
8 information, including modified safeguards, requiring that they submit  
9 fingerprints for access to safeguards information.

10 To expedite implementation where licensees need to receive  
11 safeguards information, some licensees have been called and verbally  
12 requested to submit their fingerprints.

13 In addition, the staff is quickly drafting an immediately  
14 effective final rule so that certain groups of individuals could be relieved  
15 of the requirement to submit fingerprints for access to safeguards  
16 information. That would include individuals such as State officials,  
17 members of Congress, and the final rule will also permit the Commission  
18 to continue sharing SGI with its international partners.

19 The statute also requires fingerprinting and criminal history  
20 records checks for access to materials that the Commission deems to be  
21 of such significance. In response to Commission direction, we're

1 ~~currently developing orders to require fingerprinting for manufacturers~~  
2 and distributors, as well as pool-type irradiators for unescorted access to  
3 radioactive materials.

4           Could I have slide number 26?

5           Resolution of many of the issues on access to safeguards  
6 information can be made through the SGI rule, which is with the  
7 Commission now. That package is in the proposed rule stage. It will  
8 need to be issued for comment, and final rule is not expected until later  
9 this calendar year. Between now and then, as I mentioned, the staff is  
10 working on an immediately effective final rule to provide relief for certain  
11 groups of individuals from fingerprinting for access to safeguards  
12 information.

13           Fingerprinting and criminal history records checks for access  
14 to material will be addressed later in a broad rulemaking that will revisit  
15 the exceptions granted under the current Section 656 rule.

16           The next slide number 27, please.

17           Here is the schedule. The orders are being developed right  
18 now, both for access to safeguards information and for access to  
19 materials. The final rule on access to safeguards information is  
20 dependent on the timing of the staff requirements memorandum for the  
21 proposed rule. The final rule can be delivered by OGC to the

1 ~~Commission roughly four to five months after an SRM is received.~~

2           The final rule on Section 652 for fingerprinting and criminal  
3 history records check for unescorted access to radioactive material is  
4 scheduled to be delivered to the Commission in September 2008.

5           Next slide, please.

6           In summary, we immediately began in August of last year to  
7 implement the provisions of the Energy Policy Act, and we have moved  
8 rapidly as an agency to make progress. You heard today about some of  
9 those accomplishments from Steve O'Connor. In addition, we embarked  
10 on one of our most significant rulemakings in the history of our materials  
11 program.

12           Just as important under the Energy Policy Act, but not the  
13 subject of today's focused discussion, we are nearing issuance of the  
14 final rule on the National Source Tracking System, and we move forward  
15 with our Federal counterparts and States on the Radiation Source  
16 Protection And Security Task Force. We've made considerable progress  
17 in a short time, but we're not content to rest on our accomplishments.

18           Can I have the last slide, please?

19           Beyond just meeting the statutory deadlines of the Energy  
20 Policy Act, we recognize that communications, outreach, and interaction  
21 with our stakeholders are a key part of the process that leads to

1 ~~improved results. We reached out to States in an unprecedented~~  
2 manner on the NARM rulemaking and created opportunities to solicit  
3 stakeholder input.

4 Both NRC and the stakeholders would prefer more time and  
5 opportunities to exchange information. But within the timeframes  
6 created by the Act, we are maximizing the opportunity for stakeholder  
7 involvement.

8 Finally, while we can point to the progress that we have  
9 made since the act was signed into law, many challenges remain, and  
10 some of those challenges are formidable. You just heard about the rapid  
11 pace of these rulemakings. While it may be fair for staff to respond to  
12 shorter deadlines, the faster pace also pushes our stakeholders and  
13 limits our and their opportunity for input.

14 Another challenge is the complexity of the Act. Some  
15 statutory requirements for fingerprinting are being addressed through  
16 multiple rulemakings over different time periods. While these challenges  
17 are great, the staff will continue to press hard to address them and  
18 implement the Energy Policy Act.

19 Last August, when Congress passed the Act and the  
20 President signed it into law, NRC's authority expanded in a most  
21 fundamental manner, from oversight of accelerator-produced material to



1 ~~fingerprints and firearms at licensed facilities, to a multi-agency task~~

2 force, the Act expanded NRC's role and authority. The staff understands  
3 the importance of these changes, and we are diligently working to put  
4 them in place.

5 This concludes our portion of the presentation today.

6 CHAIRMAN DIAZ: All right. You want to change places with  
7 Mr. Reyes, or his --

8 MR. MOORE: I guess I'll stay here.

9 CHAIRMAN DIAZ: Thank you for that presentation. We do  
10 realize there are many challenges. However, you realize the  
11 Commission is very anxious to make sure that this is done in a timely  
12 manner. The schedule is pressing, but we keep asking what else do we  
13 need to do and how can we help you. I think that at the end of today's  
14 discussions, we really want to hear, what else do we need to do to do  
15 that? And with that, Commissioner McGaffigan?

16 COMMISSIONER MCGAFFIGAN: Thank you, Mr. Chairman.  
17 I'll note for the record that Mr. Reyes does have a moustache, too. So  
18 it's the glasses that was the difference, I guess I was noting at the  
19 outset.

20 Scott, on the issue of this quick rule for members of  
21 Congress, and State officials, and others that I think the current 73.21

1 ~~allows an exception for them in any case to receive safeguards~~

2 information, how quickly are you going to get that done? In some sense,  
3 we should have had that done earlier. It sounds like a very simple, direct  
4 final rule.

5 MR. MOORE: The Office of General Counsel is drafting on  
6 the rule. It is drafted, and it's out for comment by other offices at this  
7 time. It exempts a number of groups of individuals, and I think they are  
8 working in the timeframe of a few weeks. I'm not sure if OGC wants to  
9 provide any further information.

10 COMMISSIONER MCGAFFIGAN: Karen, do you have a  
11 date?

12 MS. CYR: I mean, I think probably tomorrow. I mean, I saw  
13 a version today, which I think includes everybody's comments.

14 COMMISSIONER MCGAFFIGAN: So it will be sent to the  
15 Federal Register tomorrow?

16 MS. CYR: No, no; it will come to you.

17 COMMISSIONER MCGAFFIGAN: Why do you we have to --

18 MS. CYR: Because it's a rule. You have to affirm it.

19 COMMISSIONER MCGAFFIGAN: Okay. It's a rule, a final  
20 rule. So we have to affirm a final rule?

21 MS. CYR: Right, right, right. But it is immediately effective.

1                   COMMISSIONER MCGAFFIGAN: Mr. Chairman, I might  
2 suggest that we add it to the agenda for tomorrow's affirmation session.

3                   COMMISSIONER MERRIFIELD: Can I read it first?

4                   (Laughter.)

5                   COMMISSIONER MERRIFIELD: Being the sole lawyer on  
6 the Commission, I feel obligated to meet my fiduciary obligation in that  
7 regard, Mr. Chairman.

8                   CHAIRMAN DIAZ: Having learned about the one page worth  
9 of the law, I think I want to wait at least until Wednesday.

10                  COMMISSIONER MCGAFFIGAN: Wednesday, it is.

11                  COMMISSIONER MERRIFIELD: I don't know if I will be done  
12 reading it by then.

13                  (Laughter.)

14                  COMMISSIONER MCGAFFIGAN: This is a really bite-size  
15 rule. I will take my fair share of blame. I'm usually pretty attentive to  
16 effective dates, but in this particular instance, I missed it. And this is our  
17 provision. We did this to ourselves. So I think it's the problem of being  
18 involved in a serious legislative process about once every 13 years, your  
19 skills get to atrophy a little bit.

20                  The Section 656 rulemaking. Since we are doing  
21 background checks on certain individuals, those who deal with non-

1 ~~exempt Section 656 materials, import and export, that must be a~~

2 paperwork collection under OMB Paperwork Reduction Act

3 responsibilities, the Office of Information and Regulatory Affairs has the

4 lead at OMB. How is that clearance being built into your process?

5 MR. MOORE: The proposed approach that we are taking  
6 now would be to do a rulemaking that just gives exceptions at this time.

7 Because we would just be giving exceptions, we would not have to go

8 through -- in the rule itself, we would not have to go through OMB

9 because we would just be accepting people, and there would not be an

10 information collection burden because we would be giving exceptions.

11 COMMISSIONER MCGAFFIGAN: For those who aren't  
12 excepted, there is an information burden that does not exist today.

13 MR. MOORE: That's correct. And for those who are not  
14 excepted, the information collection burden would be imposed through

15 the orders that they received. So there would be an information

16 collection burden in the order.

17 COMMISSIONER MCGAFFIGAN: And so you would need a  
18 number on the order?

19 MR. MOORE: Yes, sir.

20 COMMISSIONER MCGAFFIGAN: Are you working on that?  
21 As I understand your proposal, it would initially affect the manufacturers

1 ~~and distributors and large panoramic irradiator employees.~~

2 MR. MOORE: Yes.

3 COMMISSIONER MCGAFFIGAN: So how long does it  
4 normally take to get a paperwork collection number from OMB?

5 MR. MOORE: I'm not sure if admin has authority to go out  
6 on orders more quickly than others, and we can get back to you on that.  
7 But we could go through and get it fairly quickly, I believe.

8 COMMISSIONER MCGAFFIGAN: Well, I --

9 MR. MOORE: I don't think we'd have go through on a  
10 standard process on an order if we believed there was a health and  
11 safety issue on an order.

12 COMMISSIONER MCGAFFIGAN: Okay. If that's the case,  
13 that's better. Do you happen to know, Karen, whether we need to go to a  
14 --

15 MS. CYR: I don't think it applies to orders, or at least we  
16 have a fairly blank --

17 (Simultaneous discussion.)

18 COMMISSIONER MCGAFFIGAN: Well, then, that's good.  
19 Let me go back to page 21 here, the 652 rulemaking. The long-term  
20 vision is that that will affect everybody who possesses material in cat 2  
21 and above in terms of the Code of Conduct, that meets the definition of a

1 ~~radiation source under section, I think it's 651 also, a different part of~~  
2 651?

3 MR. MOORE: I think that's the staff's current thinking right  
4 now. We have not mapped out all the details of it, but that is our current  
5 thinking. The technical basis would have to be developed for it.

6 COMMISSIONER MCGAFFIGAN: But it would be very hard -  
7 - I have the language, or I had it earlier. But it would be very hard for to  
8 us make a determination under 652 that is different from the  
9 determination Congress itself made in another subsection of section - or  
10 in Section 651 just preceding.

11 MR. MOORE: That's right.

12 COMMISSIONER MCGAFFIGAN: I think, theoretically, we  
13 could because the two sections are independent sections. But it would  
14 strike me that it involves -- it would involve a stretch for the Commission  
15 to do that. If we're going to require everyone who has category 2 and  
16 above radionuclides of concern, to have some subset of employees who  
17 are subject to the fingerprinting, both in Agreement States and non-  
18 Agreement States, how many employees do you see per licensee who  
19 might be affected by that for a category 2 and above licensee? Is it  
20 about 1400, 1500, 1600 of them? I don't know what the total number is  
21 of the agreement and non-Agreement States.

1 ~~MR. MOORE: It sounds about in the ballpark.~~

2 COMMISSIONER MCGAFFIGAN: But how many individuals -  
3 - if we have 1600 licensees approximately, ballpark, how many  
4 individuals per licensee do you all envision having to be subjected to the  
5 Section 652 fingerprinting requirement and background check  
6 requirement?

7 I promised you, Mr. Chairman, I would ask a question the last  
8 few seconds.

9 MR. MOORE: I'm not sure we have an exact answer on that  
10 number of individuals, but that is certainly something we could take to  
11 get an answer on.

12 COMMISSIONER MCGAFFIGAN: Do you have a ballpark  
13 number? Presumably, it is not every individual at the site.

14 MR. THOMPSON: If we go with what's been the average  
15 experience in other areas, like with power reactors, maybe five or six at  
16 the site.

17 COMMISSIONER MCGAFFIGAN: Just to clarify it -- and this  
18 will be my last -- If it's, say, Washington Hospital Center or Georgetown  
19 or GW, take those hospitals where there are cat 2 materials or above --  
20 maybe some cat 1 blood irradiators -- how many folks in the radiation  
21 department at those hospitals would be subject to fingerprinting?

1                   MR. THOMPSON: I guess I don't have an exact number for  
2 you, sir. We can certainly come up with a number.

3                   COMMISSIONER MCGAFFIGAN: Thank you, Mr. Chairman.

4                   CHAIRMAN DIAZ: Thank you. Commissioner Merrifield?

5                   COMMISSIONER MERRIFIELD: Mr. Chairman, thank you. I  
6 think the staff did a good job this afternoon in walking us through the  
7 challenges here. I think, at least as it relates to part of this, I look  
8 forward to our second panel to help flush out what I think are some of the  
9 concerns. But while the staff is here, I just want to get a clarification as  
10 it relates to some of the concerns raised by some of the parties we'll  
11 have in the second panel relative to 651(e).

12                   In the language of the Energy Policy Act, the Act requires the  
13 Commission, to the maximum extent practicable, to cooperate with the  
14 States and to use model State standards in existence on the date of the  
15 enactment of this Act.

16                   One of the issues that has been focused on is the degree of  
17 compatibility with definitions. And I'm wondering if you can explain to me  
18 whether there, to your knowledge, was a "model State definition" relative  
19 to this material at the time that the Act was passed. Kathy Schneider?

20                   MS. SCHNEIDER: The suggested State regulations did have  
21 -- they had a definition for byproduct material that comported with the



1 ~~one that was previously in the Act to the Energy Policy Act, and they also~~  
2 had a definition for radioactive material. So they had both definitions in  
3 the suggested State regs.

4 COMMISSIONER MERRIFIELD: If you can explain to me  
5 what the differences are between what was in the model definition and  
6 what the staff is recommending the States find egregious?

7 MS. SCHNEIDER: Okay. The States -- I hate to paraphrase  
8 for them, but they'll be more than -- they'll be explaining it on the next  
9 panel. But many of the States' regulations use the term "radioactive  
10 materials" throughout their regulation, and that term encompasses  
11 byproducts or special nuclear material, both NORM and NARM.

12 For those States that are Agreement States and legislation is  
13 an adequacy element, they will enter into agreements with us using the  
14 term "byproduct material" that we had in our statute at the time, prior to  
15 '78 -- and Karen can correct me, but before the Uranium Mill Tailings Act  
16 byproduct material -- you know, after that it was differentiated into  
17 11(e)(1) and 11(e)(2). So we had Agreement States prior to that revision  
18 to the Act that entered into agreements with "byproduct material" as the  
19 definition that was all-encompassing and didn't have the breakdown.

20 The definition that was in the suggested State regs now --  
21 because that definition has not been -- they have not done any

1 ~~corresponding changes yet to the suggested State regs reflect what's~~  
2 been in effect in the old 11(e)(1) and 11(e)(2) provision for byproduct  
3 material.

4           And then, because the States have broader statutory  
5 authority under their State law, you'll see in many States they use the  
6 term "radioactive material" or "sources of radioactive material." "Sources  
7 of radiation," too. And it depends on when we are doing a review of the  
8 program what they are encompassing and how that regulation pulls in all  
9 these things, because they'll use the same radiation protection standards  
10 for their NORM, their scale, previously areas that we didn't regulate, and  
11 then their byproduct material, source material, and limited quantities of  
12 special nuclear material.

13           Does that answer the question?

14           COMMISSIONER MERRIFIELD: To a certain extent, I guess.  
15 Basically, what you are saying is that many States have a broader  
16 umbrella in their description.

17           MS. SCHNEIDER: Correct.

18           COMMISSIONER MERRIFIELD: What we are asking for ---  
19 and this is a more specific description of the material that we're intending  
20 to focus on here.

21           MS. SCHNEIDER: Right. Under our definition of byproduct

1 ~~material, it's very specific. The States historically have had a very broad~~  
2 authority for all sources of material, both those that we regulate and  
3 those that we have not regulated. So the suggested State regs have had  
4 both the byproduct definition there and have had radioactive material.

5 I personally am aware of one or two States that I have seen  
6 where they define the term "byproduct material" and they don't use it in  
7 their sections of their regs because they are using "radioactive material,"  
8 which is broader.

9 COMMISSIONER MERRIFIELD: In the comments that we  
10 received – and we have that letter from the Organization of Agreement  
11 States which listed the specific comments by State, one of those, that of  
12 Maine, had an idea that we -- suggesting that the NRC ought to find out  
13 what the States have for definitions and an estimate of whether the  
14 definitions are all similar or exactly the same.

15 Did we actually try to do some understanding about where  
16 the States were on this, and whether, in fact, as Maine asserts, they're  
17 more similar or exactly the same?

18 MR. MOORE: We did. As part of the rulemaking effort, we  
19 went back through and looked at the various State regulations, not just  
20 on definition but also on regulations. I'm not sure whether the definitions  
21 for byproduct material were exactly the same or not.

1 ~~What we would have found on that would have been that~~  
2 byproduct material would have been defined in the former definition that  
3 we had used. And had we found that, then I think the staff's conclusion  
4 on that would have been that byproduct material would need to be  
5 changed.

6 The definition for radioactive material will probably be broad  
7 enough that it would be acceptable. I think the question is, how are they  
8 used throughout the States' regulations, not just the definition itself.

9 So, we did go back as a staff in the rulemaking and look at  
10 the States' regulations and how they used the model State regulations.

11 COMMISSION MERRIFIELD: Thank you, Mr. Chairman.

12 CHAIRMAN DIAZ: Thank you. Commissioner Jaczko.

13 COMMISSIONER JACZKO: I wanted to just go back and  
14 revisit the 656 versus the 652 rulemaking, and I just want to make sure  
15 that the staff has thought through this issue. Perhaps you can clarify  
16 that for me in answering my question.

17 The primary issue has to do with, we will accept certain  
18 materials under 656 and do a fairly quick rulemaking, if you will, to try to  
19 get that done close to the statutory deadline, then come later and do a  
20 652 rulemaking, which will be more encompassing.

21 Now, if the 652 rulemaking winds up un-exempting people

1 ~~who have exempted material, if you will, will that be something that will~~  
2 be able to do without any potential problems about the various  
3 rulemakings being inconsistent, having accepted, in one case, this  
4 material and then later essential un-accepting that material.

5 MR. MOORE: The 656 rulemaking, as we are envisioning it  
6 now, would -- For starters, I guess I should give some background  
7 material. The 656 rulemaking only applies to material that is received or  
8 accompanied pursuant to an import or export license. So, 656, because  
9 of the way the statute is written, does not affect domestic transportation  
10 now. 652 could and probably will with respect to background checks and  
11 fingerprinting. 656, with regard to material pursuant to an import and  
12 export license, the staff is envisioning, in response to the public -- in  
13 response to the Agreement State comments that we received, or  
14 stakeholder comments -- applying it to only the higher risk categories of  
15 sources.

16 COMMISSIONER JACZKO: 656?

17 MR. MOORE: 656.

18 COMMISSIONER JACZKO: Right, that is my question. I  
19 mean, we're really only talking about --

20 MR. MOORE: Manufacturers and distributors in RAMQC at  
21 this time.

1                   COMMISSIONER JACZKO: Those are all category 1

2 sources, or are there some category 2 sources?

3                   MR. MOORE: The manufacturer and distributors could catch  
4 some category 2.

5                   COMMISSIONER JACZKO: To put my question more  
6 specifically, are there category 2 sources that will be accepted under 656  
7 that we might then, when we go back and look at 652, want to recapture  
8 some of those types of practices? And that is something that -- Karen,  
9 perhaps this is a question for you -- that we will be consistent with being  
10 able do that from a standpoint of an arbitrary and capricious definition in  
11 the rulemaking process.

12                   MR. MOORE: I think the answer -- and then OGC can give a  
13 legal view. I think the answer is there could be, under 652, some that we  
14 will pick up later when we revisit the exceptions. But with respect to 656  
15 now, there are some category 2, but very, very few.

16                   COMMISSIONER JACZKO: That will be accepted or that will  
17 be captured?

18                   MR. MOORE: That will be accepted at this time, because we  
19 are only looking at the higher risk sources that would be captured at this  
20 time. We went back and looked at who was importing and exporting.  
21 And the staff actually looked at one month -- I think it was February --

1 and who had applied for licenses to import and export.

2                   And then we compared that against who would be picked up  
3 against this group that would receive these orders under higher risk  
4 sources, and there was a one-to-one match. Essentially, it was a  
5 hundred percent of people that applied to import for the month of  
6 February would receive that. So I mean, we are at a hundred percent for  
7 there. We can't assume that every month, there would be a one-to-one  
8 match, but we believe, looking at general data, that it would be in the  
9 high 90 percentiles; roughly around 98, 99 percent or so.

10                   COMMISSIONER JACZKO: Karen, maybe you could  
11 just –

12                   MS. CYR: I think, as long as you, in your subsequent  
13 rulemaking, where you may cast for a broader category of people who  
14 previously weren't captured, I think, as long as you have an adequate  
15 basis in your rule for why now you feel that your health and safety  
16 justifies you to capture a broader category of individuals, it would  
17 through – they'll have an opportunity to raise their concerns of why. And  
18 we have to justify why it has not covered before and why we now have a  
19 basis.

20                   So as long as I think we have a reasonable basis for why  
21 now, looking at it in this broader category of reexamination, we think that

1 ~~they fall within a group which needs to be covered by this, I think we can~~  
2 justify that from a legal standpoint as a process.

3 MR. MOORE: I should qualify my answer. I was looking at it  
4 in terms of total curie content, not in terms of total numbers of licensees.  
5 So if you look at it in terms of higher risk sources in terms of total curie  
6 content, we would say the high 90 percentile in terms of total curie  
7 content.

8 COMMISSIONER JACZKO: But not necessarily in terms of  
9 total number of licensees?

10 MR. MOORE: Right.

11 COMMISSIONER MCGAFFIGAN: Mr. Chairman, for  
12 somebody watching this in the public, or listening to or reading this  
13 transcript, the proposal that the staff is talking about, the law allows us  
14 to exempt classes of material and classes of licensees, classes of  
15 individuals. And what the staff is likely to do is to say all byproduct  
16 sources less than category 2 are exempt, so category 3, 4, 5 sources are  
17 exempt. And within category 1 and 2 sources, you are planning to  
18 exempt those classes of licensees for whom the Commission or the  
19 States issued orders under public health and safety authority, as  
20 opposed to common defense and security authority last year.

21 MR. MOORE: We are working on the words. I'm not sure



1 we'll use those exact words.

2 COMMISSIONER MCGAFFIGAN: Well, I'm not sure of those  
3 exact words, but that is the spirit that you're going under.

4 MR. MOORE: Yes, sir.

5 COMMISSIONER MCGAFFIGAN: So you are exempting  
6 -- In the materials and the source materials, you're exempting all  
7 materials category 3 and below, and then, in the individuals, even if they  
8 have category 1 and 2 material, you are exempting those who receive  
9 public health and safety as opposed to common defense and security  
10 orders?

11 MR. MOORE: Yes, sir.

12 CHAIRMAN DIAZ: Commissioner Lyons?

13 COMMISSIONER LYONS: Let me first congratulate the staff,  
14 both on the presentation and the progress that you have made in working  
15 towards the various deadlines in the Energy Policy Act.

16 One perhaps very trivial question: Scott, on I think it was  
17 slide 4, you mentioned the radium-226 and antiquities. I have no feeling  
18 for how large a range of strengths we are talking about represented in  
19 antiquities. Do you have any feeling for what that number is?

20 MR. MOORE: We have some anecdotal evidence, but I don't  
21 -- specifically, it's very low. But we just had anecdotal evidence; we

1 ~~didn't have enough of a basis to make an exemption. So I don't, no, sir.~~

2 COMMISSIONER LYONS: I guess my gut feeling is that it  
3 would have been a very low source strength, and probably quite easy to  
4 treat in a simple way; at least that would have been my hope.

5 Turning then to the NARM rulemaking, I understand the  
6 States' interest in compatibility D, and I understand the staff's argument  
7 against the use of compatibility D. And as explained to me, I don't see  
8 how compatibility D could possibly be allowed for this particular case.

9 But the States have made an alternative proposal on one of  
10 their slides, and because we're dealing with two different panels here, I  
11 wondered if it would be out of place to ask you if you would be willing to  
12 comment on the alternative proposal that the OAS or CRCPD made on  
13 your slide 6. And since not everybody may have that, let me just say that  
14 as an alternative, they are recommending that the Statements of  
15 Consideration should acknowledge that certification by the Governor that  
16 the State has an adequate NARM program which should preclude  
17 definitional changes.

18 I was curious whether staff had had an opportunity to  
19 evaluate that proposal from OAS or CRCPD.

20 MS. SCHNEIDER: If that's okay, I'll take this one. Really,  
21 this is looking at what we consider the implementation of health and

1 ~~safety and our determinations as to whether this program is adequate~~

2 and compatible. And I'll say we take a look at this as we do all new  
3 rulemakings, and we categorize all of it. And then we take a look as to  
4 where they fall out.

5           This would be one of the things we're expecting whenever  
6 this rulemaking is finished and whatever the Commission decides on the  
7 various -- on both compatibility and adequacy designations. Then we're  
8 going to take a look and see how the States address it.

9           If it is a health and safety, something like this would be  
10 something that I think we could -- you know, if the State goes through  
11 and says they've covered sources of radioactive material, actually meets  
12 and is all-encompassing, and that we then cover -- I think what they are  
13 looking for is some sort of comfort that we are not going to be changing  
14 when we do our implementation, that this a health and safety and that  
15 there is a lot of flexibility in addressing the essential elements of this  
16 program element, which is, have you covered this material such that  
17 there's not exposures to the public and public health and safety are  
18 being protected.

19           COMMISSIONER LYONS: That is consistent with my  
20 understanding, too. I do support the staff's recommendation of the H&S  
21 approach to this. And to the extent that this alternative can be

1 ~~considered in that process, I think that would be --~~

2 MS. SCHNEIDER: I think the staff, as we preliminarily talked  
3 about it, believe this is part of our normal implementation, which we look  
4 at whether it's through regulation, legally binding requirements. Some  
5 States have statutes. The State will have to -- Each Agreement State  
6 will have to take a look at each of the elements, but this is certainly  
7 something that would be an acceptable approach, I believe -- that they  
8 have the certification by the Governor, plus any other additional  
9 supporting elements for covering these materials.

10 COMMISSIONER LYONS: I appreciate that response. And I  
11 did want to make it clear that I do not support the compatibility D  
12 suggestion from the States, but the suggestions are quite reasonable.  
13 Karen, did you want to add to that or is that sufficient?

14 MS. CYR: And Kathy addressed it. And the question is  
15 whether -- in our follow-up reviews, whether, in a sense, it minces a  
16 legally binding requirement? This would represent a judgment on their  
17 part at the time they certified that, in fact, it complies with the health and  
18 safety version of our things. And I think that's certainly something we  
19 could accept with the staff looking at it.

20 But, again, as an ongoing IMPEP process, you might go back  
21 and look at that at some point. But I think that the issue is, that would be

1 ~~a way for them to represent that, in fact, they are meeting this element of~~  
2 the program.

3 MS. SCHNEIDER: I can tell you from experience that we  
4 have had States that have occasionally made changes in regs or in  
5 legislation that, under IMPEP, we've identified, and we have had to go  
6 back with them and say, this didn't meet this element, compatibility  
7 element, or this didn't meet this health and safety element.

8 We've had both of those calls where we have had to bring  
9 that to the State's attention, and they have had to address that to bring  
10 them back into performance standards of adequacy and compatibility.

11 COMMISSIONER LYONS: Thank you very much. That's all,  
12 Mr. Chairman.

13 CHAIRMAN DIAZ: Thank you, Commissioner Lyons. Let me  
14 go back to one point that Mr. Moore made. And I'm sure that you really  
15 meant what you said, but I wrote it down, and that's dangerous. And it's  
16 May of 2006, and we are really getting ready to roll these things out.  
17 And if I may quote you, you said we have not mapped out all the details.  
18 Now, that's what you said: we have not mapped out all the details. I  
19 understand that.

20 My point is that in some reasonable time in the future, we  
21 need to map out all the details. The clock is ticking, and I know

1 ~~everybody has been working on different things. But this would be~~

2 consistent with Commissioner -- all the Commissioners in a certain way.

3 It's time to put this in one of my favorite tools, a matrix, and make sure

4 that all the details are there and that there is a consistency, both

5 internally and externally. So, hopefully, next time you come to the

6 Commission, the first statement will be for the Commission, we have

7 mapped out all the details, and we have also implemented them. I'm

8 looking forward to hearing that from someplace.

9 Let me go back now to the same point that consumed a little

10 bit of us, which is the issue of the stakeholders from the States and the

11 issue of compatibility D, and public health and safety, and all the things

12 we have talked about. I do believe that the law has some words that I

13 think are very, very strong that they use to the maximum extent

14 practicable, to use model State standards.

15 I think, in a certain way, that is asking us to go beyond where

16 we have always been. I think this Commission and the relationship with

17 the State is mature enough that we can go beyond where we normally

18 are, and compatibility D just does not cut it.

19 The States by themselves putting something that is out there

20 and does not allow us to make some checks that provide the basis for

21 our assurance of public health and safety won't do it.

1 ~~But if there are mechanisms that we can incorporate, a kind~~  
2 of formal review of the IMPEP program, for example, as Karen  
3 mentioned, there must be ways in which we can actually reframe this,  
4 where we can use the best of the State, comply with the intent of the law,  
5 and provide for the NRC level off -- and I'm not going to use the word  
6 compatibility -- a level of interchangeable standards for radiation  
7 protection for public health and safety that will allow this to work. I'm not  
8 sure what they are, but I believe they do exist. I think sometimes we get  
9 in boxes, compatibility D, compatibility B, compatibility -- you know.

10           And there is a time in which, you know, we need to come up  
11 and say, the law says this; this is where we are. We now know better.  
12 We now have what I hope is a better relationship with the States. We  
13 know how to do this thing, and we have a longstanding, very proven  
14 IMPEP program. I believe that it is a way out.

15           And Commissioner McGaffigan, I think I'm learning from you:  
16 I'm making statements instead of questions of late. It must be  
17 contagious. So, is that something that could function?

18           MS. SCHNEIDER: Chairman, I personally believe we do that  
19 now. I believe that's how we have implemented it in the past. And my  
20 position is involved in both project managing IMPEP and doing reg  
21 reviews now, and that is how we handle it. And the essential elements of

1 ~~the program itself and health and safety will allow us to work reasonably~~

2 and to -- I'm blanking on the word; I apologize. I'll ask Janet to stand up  
3 a little bit -- allow us to attain the objectives I think that will allow to us  
4 implement this, and in a less disruptive way as possible with the States,  
5 because we do believe, at least from our standpoint in State and Tribal  
6 Programs, that many of the things are already covered within the State's  
7 regulations because of the way they have been regulating these  
8 materials over the years.

9 MS. SCHLUETER: True, exactly. I think that we are in a little  
10 bit of a unique situation here because the states have been regulating  
11 these materials that are now under the Atomic Energy Act and the NRC's  
12 purview. So we are looking for ultimate degrees of flexibility under the  
13 current adequacy and compatibility policy statement, and I think we do  
14 have that under health and safety.

15 It's not only the IMPEP review that will take place, but before  
16 we even get to that point, just like every other rule that we put out there,  
17 the States have to then ensure that they have addressed the elements of  
18 the rule. And in the NARM paper that you have before you, if you look on  
19 page 87 of that paper, that's where we have a chart with regard to the  
20 elements that are in the NARM rule.

21 And with every rulemaking, the Agreement State then sends



1 ~~in the rule package within the three years that they have to implement~~

2 the final rule. And they do a crosswalk, and they go down our rule and  
3 they look in their own rules, and they determine where is it addressed in  
4 their own rules.

5 So between what they have on the books today and what  
6 they have for NARM and what they have on the books under their  
7 agreement, we will probably find that in almost all cases, they will have  
8 covered and addressed the NARM material that's now under AEA in  
9 some form or another, whether it's under the definition of byproduct  
10 material or radioactive material. It must be covered because they have  
11 been regulating it.

12 And then there is the issue of the State law and whether or  
13 not they have to go back and amend that in some way to change their  
14 existing definition of byproduct material. Again, we are looking for ways  
15 to implement that in a flexible manner because they have been  
16 regulating it for 50 years. And it may be enough for the Governor to send  
17 in that certification and determine -- make their own independent  
18 determination that their program is adequate. So we're working with OGC  
19 and the States to do that.

20 CHAIRMAN DIAZ: All right, thank you. Now, I believe that  
21 was a very long answer by staff, if I may say so. But I got it. I don't

1 know if my fellow Commissioners have some very brief pointed  
2 questions.

3 COMMISSIONER MCGAFFIGAN: I just have -- With regard  
4 to the new radionuclides we are adding, do you have exempt levels and  
5 levels requiring specific licenses for these radionuclides similar to what  
6 might be in Parts 30, 31, 32? I saw that you had some exempt  
7 concentrations. I didn't see an exempt concentration of, say, radium-  
8 226. Is there an exempt level for radium-226? No? That goes to your  
9 point that didn't know where to draw the exempt line?

10 MR. MOORE: That's correct, because we don't have the  
11 specific information on the number of sources that are out there and how  
12 they are used out there.

13 COMMISSIONER MCGAFFIGAN: How much fluorine-18 do I  
14 need -- fluorine18 is in our current rolls because a reactor can produce  
15 it, too. But how much fluorine-18 do I need to require specific licensing,  
16 as opposed to general licensing? Does that concept stick -- go through  
17 these rules?

18 MR. MOORE: We can get back to you with an answer.

19 COMMISSIONER MCGAFFIGAN: I saw thresholds. You  
20 added some radionuclides for the exempt concentrations.

21 MR. MOORE: Right.

1                   COMMISSIONER MCGAFFIGAN: You added radium-226 for  
2 the general license tracking system at 100 – no, no; one millicurie?  
3 What was the number for radium-226? You added it in the general  
4 license tracking system. I just missed anything for the general  
5 license/specific license line. So I just would be interested in that. And  
6 I've got 15 seconds. I had a second question, but I'm getting old. Twice  
7 in a week now I have forgotten the second question. So I guess I'll pass.

8

9                   CHAIRMAN DIAZ: Commissioner Merrifield?

10                  COMMISSIONER MERRIFIELD: Pass.

11                  CHAIRMAN DIAZ: Commissioner Jaczko?

12                  COMMISSIONER JACZKO: I'm going to try to get two  
13 questions in, so very brief answers, if you would.

14                  On the radium-226 for some of the consumer products, you  
15 said the staff does not have an adequate technical basis to make a  
16 determination for exempt -- to determine exempt quantities. Can you  
17 just briefly talk about -- Effectively, these are going to be under general  
18 license. But what would be the practical difference between exempting  
19 them and general licensing?

20                  MR. MOORE: In generally licensing, we can actually put  
21 some kind of requirements on them. Exempting them, we have no

1 ~~requirements at all on them.~~

2 COMMISSIONER JACZKO: What's missing? What is this  
3 kind of information you don't have in order to make it?

4 MR. MOORE: We don't have information on the number of  
5 sources that are out there, the exposure rates from the sources, as  
6 Commissioner Lyons mentioned. The number of -- how they are  
7 disposed of. We have anecdotal information.

8 COMMISSIONER JACZKO: And I appreciate that. From  
9 there, if we impose a general license -- ultimately, those are the kinds of  
10 things we need for the general license, as well. How are we then going  
11 to figure out how many sources there are, who's got them? I mean, if we  
12 impose a general license, what would be the practical effect, then, on  
13 people who have some of these things?

14 MR. MOORE: I think one of the practical effects is that we  
15 can take regulatory action as a regulator and enforce our rules with -- we  
16 have an enforcement mechanism. With an exemption, we don't have  
17 such an enforcement mechanism.

18 COMMISSIONER JACZKO: I appreciate that. I guess my  
19 point is, I have some concern about whether we're ever going to be able  
20 to find out who take enforcement action and all these things if we don't  
21 know who they are.

1           ~~The other question I want to ask -- and this is perhaps~~  
2 something to get back to later. But this again goes to this issue of the  
3 compatibility and the adequacy of determinations. I was just going  
4 through the policy statement on adequacy and compatibility. One of the  
5 things it says in there is, we need to make adequacy determinations and  
6 compatibility determinations.

7           And I guess I still have a little bit of confusion on my part  
8 about why there is not a need in this particular case to have some level  
9 of compatibility, in addition to an adequacy determination that  
10 essentially comes through the health and safety determination. Again,  
11 we are talking about a definition here for byproduct material, and it  
12 seems to me, to some extent, this is now regulated under the Atomic  
13 Energy Act. There does need to be a level of compatibility among States  
14 about what materials fall under their Atomic Energy Act provisions and  
15 what materials don't.

16           Certainly, I think probably one of the simplest things is just to  
17 look at accelerators. I mean the staff is looking at accelerators, that will  
18 be used to irradiate targets and produce byproduct material. Activation  
19 components, I think, as I recall, from those accelerators will be included  
20 in the definition, but if it is an accelerator that is not irradiating the target  
21 that's covered, the activation products from that will not be included.

1 ~~So there are issues about what goes into the definition. And~~

2 I think from the perspective of the Atomic Energy Act, we would want to  
3 have some compatibility. I've probably taken too much time on this, but  
4 if there is a brief answer from the staff -- if not, that's something you  
5 could get back later -- why we don't need a compatibility A or B  
6 determination.

7 MS. SCHNEIDER: I think we go back to fact that we look at  
8 that again although that legislation is an adequacy element, when we did  
9 the policy statement back in '97, they have to address what categories  
10 they'd enter into an agreement. But you go back to, is it going to create  
11 -- is it basic radiation one for the A requirements, the B trans boundary --

12 COMMISSIONER JACZKO: I guess it is the B. It seems  
13 there could be issues about --

14 MS. SCHNEIDER: What if they're using the term radioactive  
15 sources? And I've used as an exaggerant-- What if they called it Green  
16 Glowing Goop, and under their State definition, they have covered all the  
17 aspects? And the States do. They do the sources, the electronically  
18 produced, NARM, NORM. They have for years.

19 Now, is that going to create a problem with compatibility in  
20 the national programs? Is it going to create problems in other  
21 jurisdictions by them not using the term "byproduct material"? It's not.

1 They put "radionuclide" on their license. They don't use the term

2 "byproduct." They say they're regulating radium-226, and they've been  
3 able to do that.

4 So from that standpoint, we believe they need to have it from  
5 an adequacy standpoint, but not from compatibility. They don't all have  
6 to use that term because they are covering it in their regulations.

7 CHAIRMAN DIAZ: Commissioner Lyons?

8 COMMISSIONER LYONS: I don't think I have any questions,  
9 but perhaps a comment on the point that Commissioner Jaczko was just  
10 addressing on the need for, perhaps, compatibility in addition to  
11 adequacy. At least in my own mind, it would be sufficient to stay only  
12 with the adequacy statement because of the very strong statements in  
13 the legislation about the Commission, to the maximum extent  
14 practicable, cooperating with States and using model State standards.

15 To me, that is almost arguing against a compatibility  
16 designation and also why I was comfortable with an "adequacy" --

17 MS. SCHNEIDER: And I believe, if I remember correctly,  
18 that the Governor certifies that they have an adequate program, not an  
19 adequate and compatible program, according to the language in the  
20 legislation.

21 COMMISSIONER MERRIFIELD: Mr. Chairman, having

1 ~~yielded some of my time, I'll take some of it back. I was going to wait for~~  
2 the next panel to make their points, but: Focusing on this language the  
3 use of "to the maximum extent practicable," it does not say "the  
4 Commission shall use," and that is a very important distinction. It  
5 requires the Commission to do an independent assessment of this  
6 language, not merely to take up the State's path. I think that's an  
7 important distinction.

8 CHAIRMAN DIAZ: Thank you, Commissioner Merrifield. I  
9 want to thank the staff. I tend to repeat myself occasionally these days.  
10 I do believe it is important that we frame every single aspect of this issue  
11 so that when the time comes, we can just say we have done this, and we  
12 know that.

13 There is an issue of information and communication, and  
14 assembling that information to make sure that everything is done. I'm  
15 sure the staff has worked very hard on it. Now that you have all of the  
16 things, it's time to find out what you don't know, what you should know,  
17 how you get it, and eventually, how you put it together. With that, I want  
18 to thank the staff and call for the next panel.

19 We'll get a two-minute recess right now. Thank you.

20 (A short recess was taken.)

21 CHAIRMAN DIAZ: All right, good afternoon again. The



1 ~~Commission is pleased to meet with different stakeholders, mostly from~~  
2 the State: Mr. Thompson, the previous chairman of OAS; Mr. O'Kelley,  
3 the present Director of CRCPD; and Ms. Schwarz, ACMUI; and Mr.  
4 Brown from CORAR. We appreciate the time that you have put into  
5 coming here and preparing to meet with us. We look forward to a lively  
6 interchange. And with that, I don't know who is designated to go first.

7 MR. THOMPSON: I'm first up.

8 CHAIRMAN DIAZ: All right.

9 PRESENTATION BY JARED W. THOMPSON

10 MR. THOMPSON: Good afternoon Mr. Chairman,  
11 Commissioners. On behalf of Barbara Hamrick, Chair of the  
12 Organization of Agreement States, the OAS Executive Board, and Board  
13 of Directors of the Conference of Radiation Control Program Directors,  
14 we would like to thank you for the opportunity to speak with you about  
15 the many important issues facing the Agreement States and the NRC at  
16 this time.

17 I would like to focus this discussion on issues related to the  
18 proposed rulemaking, implementing Section 651 of the Energy Policy Act  
19 of 2005, especially that subsection related to the incorporation of  
20 naturally occurring and accelerator-produced radioactive material, or  
21 NARM, into the definition of byproduct material.

1 ~~I will briefly address issues relating to secure transfer~~  
2 requirements of Section 656 fingerprinting and criminal history records  
3 check in Section 652.

4 As mentioned previously in NRC staff briefing, the  
5 Organization of Agreement States and Conference of Radiation Control  
6 Program Directors identified several staff individuals to work with the  
7 NRC on a variety of activities associated with the proposed rule. We  
8 greatly appreciate the opportunity afforded to us to collaborate with the  
9 NRC on the efforts related to this rulemaking.

10 The States have a serious concern relating to the proposed  
11 compatibility and/or adequacy designation for the proposed definition of  
12 byproduct material.

13 Other definitions resulting from this rulemaking may pose  
14 similar problems, but for the sake of this discussion today, we will focus  
15 here on the proposed definition of byproduct material.

16 Next slide, please.

17 For over 40 years, the States have regulated NARM, which  
18 just now has come under the purview of the NRC. In order to  
19 accommodate the broader state authority under those -- to  
20 accommodate State authority during those years, the States generally  
21 relied upon a generic term, "radioactive material," to define the regulated

1 ~~material. Since this term is, by State standards, inclusive of byproduct~~  
2 source materials, special nuclear material, and both discrete and defuse  
3 NARM.

4 NRC Management Directive 5.9 formerly acknowledges this  
5 in Handbook Part 6, where it states, and I quote, "Changes to reflect  
6 increased scope of State authority, especially the use of the term  
7 'radioactive material' in the place of the term 'byproduct material' would  
8 not be considered significantly different for the purposes of evaluating  
9 compatibility, requiring that a regulation be essentially equivalent."

10 This kind of gets us away from the compatibility A and B,  
11 which was talked about briefly by Kathy Schneider. It was therefore  
12 somewhat disconcerting to learn that during the deliberations on the  
13 compatibility or adequacy designation for the definition of byproduct  
14 material, NRC staff, proposing a C designation, which is not as restrictive  
15 as an A or B, were of the opinion that this would still require the States to  
16 amend their definition of byproduct material in statute and regulation to  
17 conform with the definition of the proposed rule.

18 The concerns of the States primarily rest with the idea of  
19 having to change statute. I know in my State in Arkansas, when we  
20 became an Agreement State in 1963, in the Act that made us an  
21 Agreement State, there is a definition of byproduct material. There is

1 ~~also a definition of radioactive material. That's what our regulations~~

2 hinge on. The currently proposed category health and safety adequacy  
3 designation would require that the States adopt the essential objectives  
4 of the rule in question. This is essentially the same language used in the  
5 description of the compatibility category C designation, which NRC staff  
6 had already indicated would require a change in the definition in the  
7 State statute and regulation to conform to the NRC definition. That is  
8 where the concern of the States lies: going back and having to change  
9 statute.

10 This is a very large and significant departure from the policy  
11 laid out in the Management Directive 5.9 and may impose a very  
12 significant burden upon the Agreement States.

13 Next slide, please.

14 After the discussions with the NRC staff regarding the  
15 proposed interpretation of a category C compatibility designation and the  
16 alternative proposal to assign a definition of category H, health and  
17 safety adequacy designation, the OAS went to the Agreement State  
18 program directors for input. Thirty-three of the 34 States indicated that a  
19 category D was the appropriate designation. If you look on the slide, you  
20 see there that 27 of the 34 Agreement States indicated that it might be  
21 necessary to seek legislative change for the amendment to State statute

1 ~~for the proposed definition of byproduct material.~~

2 I understand that the NRC is on a fast track to try to get this  
3 rule in place. State legislatures move a little bit slower most of the time  
4 than Congress does. I know in my State, it meets once every two years.  
5 So there is going to be a lag period if we have to go in and start changing  
6 statutes.

7 Let me reiterate here that the NARM now, under the  
8 jurisdiction of the NRC, discrete radium sources and accelerator-  
9 produced materials extracted for commercial use, are currently regulated  
10 by the Agreement States under the same programs as the byproduct  
11 material and have been for well over 40 years.

12 I'm going to make another statement here, too: No matter  
13 what definition of byproduct material you may define, our radioactive  
14 material is going to cover more than what your byproduct definition is  
15 going to do.

16 There's some elements here, particularly when you start  
17 talking about defuse NORM, that is not going to be under your authority,  
18 but still will remain under States. It's going to fall under our radioactive  
19 material definition.

20 As stated in the supplementary information section of the  
21 proposed rule, and I quote, "The regulatory structure used by the

1 ~~Agreement States does not distinguish between NARM and other~~

2 radioactive material. This regulatory structure subjects NARM users in  
3 the States to the same licensing, inspection, and enforcement policies as  
4 those using other byproduct source or special nuclear material.”

5 As one of our former program directors used to say,  
6 “Radioactive material is radioactive material, and we regulate it the same  
7 way.”

8 In short, the Agreement States already have in place a  
9 regulatory structure that includes NARM and is consistent and  
10 compatible with the regulation of other byproduct material, as each of the  
11 Governors will certify to the Commission upon the publication of the  
12 NARM transition plan.

13 Next slide, please.

14 This slide, we have seen before, and it relates to -- and it  
15 has been quoted many times up here, so I’m not going to go into it. But  
16 to the extent practical, I think it has already been discussed, and we’re  
17 just going to move on.

18 Next slide, please.

19 To this end, the States recommend that the compatibility  
20 designation for the definition of byproduct material be a D, not required  
21 for purposes of compatibility, and that no adequacy designation be

1 assigned.

2 I do want to make one clarification here. When I was  
3 discussing the compatibility C designation, there was obviously a  
4 miscommunication on what a compatibility C designation should be. And  
5 that raised some concern with the States, was how that was misspoken.  
6 And I know that STP, State and Tribal Programs, has done a good job of  
7 trying to let the States understand that that was just a  
8 miscommunication. That is probably why we are at some  
9 of the impasse that we are at today on the compatibility designation of  
10 this definition. Some of us -- and I happen to be one of them -- would  
11 not have a problem with the compatibility C. That's just me, so I can't  
12 speak for the rest of the States. Next slide, please.

13 The OAS Executive Board would like to suggest an  
14 alternative approach to the adequacy issue. We suggest that the  
15 Statements of Consideration clearly state that if a Governor certifies that  
16 the State has an adequate NARM program as required by the Energy  
17 Policy Act, that no definitional changes would be necessary in statute or  
18 regulation to meet the adequacy requirements. For example, if the  
19 States' current legislative authority encompasses NARM, it would not be  
20 necessary or required to make changes to statutory -- and remember,  
21 that's where the real issue is, a statutory change -- and regulatory

1 ~~definition of byproduct material and to other definitions designated as a~~  
2 health and safety.

3 I'd like to briefly address Section 656 and 652 of the Energy  
4 Policy Act. Section 656 deals with the secure transfer of materials  
5 crossing our nation's borders, but in many ways, the requirements  
6 parallel those found in Section 652, which requires fingerprinting and  
7 criminal history checks for persons who have access to radioactive  
8 material within the United States.

9 Next slide, please.

10 We support the NRC staff's recommendation to proceed with  
11 Section 656 by issuing enhanced security orders to the high risk, high  
12 priority licensees already subject the NRC's common defense and  
13 security orders, and then further address the requirements in rulemaking  
14 in parallel with the rulemaking efforts in Section 652.

15 The OAS and CRCPD look forward to working cooperatively  
16 with the NRC staff on this rulemaking. And I will yield the remainder of  
17 my time to Mr. O'Kelley.

18 PRESENTATION B MR. O'KELLEY

19 MR. O'KELLEY: You left me too much time. I want to  
20 reiterate the compatibility issue and what got the States all up in arms  
21 was when we were told that, to some, the category C definition was equal



1 ~~to a category A or B, and if that was the way it was going to be~~

2 implemented, then that was going to cause some major concerns.

3 I think the bottom line is that we don't want -- we prefer that  
4 a mechanism be found that we don't have to go and needlessly change  
5 statutes and regulations for something we have already been covering  
6 for years. Looking at the Energy Policy Act, we could say, well, maybe  
7 the intent was that NRC become compatible and adequate with the  
8 States, but we won't go that far.

9 But I do think we're on a path, and we can find a mechanism  
10 where we don't have to needlessly go and change rules and regulations  
11 to cover it because we want to make this performance-based, and as  
12 long as we are covering it and regulating it the way you want to, then I  
13 think we have accomplished our purpose. And I do believe that 99.9  
14 percent of the State statutes and regulations definitions do cover what  
15 you will be changing to your definition of byproduct material. Enough  
16 said.

17 The second area of concern is the Governor's Letter of  
18 Certification. I think Commissioner Lyons heard a lot of the States'  
19 concerns on that issue -- and again, I think it's an implementation  
20 concern, that we find a way to make this as painless as possible and  
21 accomplish the intent of the Act. And I know there's some concerns

1 ~~about, Congressional intent was not placed in this Act, but I do think we~~  
2 all know what it means and that we find a way to minimize the impact on  
3 those States that already have programs in place.

4 I think we probably need to have a lot of discussions back  
5 and forth on what is going to be acceptable to primarily the lawyers  
6 involved, I guess, in this. One suggestion I have is that you accept a  
7 letter from the Governor that says, on the date that the transition plan is  
8 published in the State register, I certify that we are adequate and  
9 compatible.

10 There were a lot of questions that you have to have that very  
11 date on the letter, and he can't sign it until that date is published in the  
12 State register. And then, does it have to be in NRC's hands on that date,  
13 and what happens if it comes in a day later. So these are some of the  
14 questions that are out there, but I'm pretty sure that the rational minds  
15 here can come up with a solution to that to make it very workable and  
16 doable and accomplish the intent of the Act.

17 I'll ditto Jared's 656, 652. We are in agreement with the  
18 proposed way to deal with 656 through orders at the present time. And  
19 just to go a little bit further, it was our intent or hope that 652 will also be  
20 only implemented against those licensees that are currently under  
21 increased controls.

1 ~~Criminal background checks is going to be an issue. We~~  
2 want to find a way or suggest that we find a way and I know it says  
3 through Federal means, but in talking with some of the members on the  
4 Chairman's Task Force, the FBI, they said that same information is  
5 available to our State FBI counterparts. And I think it would probably do  
6 a lot to ease up the burdens that are going to be on everybody when we  
7 start requiring all of these people to be fingerprinted. And I think some  
8 already have been through the increased controls. But any way to ease  
9 that process and accomplish the same goal is what we are asking for.

10 We have got several issues on the Energy Task Force, but I  
11 think I will wait until that comes to bear. We I guess mainly want to say  
12 thanks for allowing to us participate on that. We appreciate it, and we  
13 appreciate the opportunity to talk to you here. And I see I am out of  
14 time, so I'll hush.

15 CHAIRMAN DIAZ: Thank you, Mr. O'Kelley and Mr.  
16 Thompson. Dr. Schwarz?

17 PRESENTATION BY DR. SCHWARZ

18 DR. SCHWARZ: Thank you. I'm here as the Nuclear  
19 Pharmacy representative from the Advisory Committee on the Medical  
20 Use of Isotopes. Today, what I would like do is just present some of the  
21 stakeholders' points of view.

1 Overall, PET, kind of a new entity for the NRC to begin  
2 regulating, is an integral part of clinical nuclear medicine. This field is  
3 rapidly advancing the diagnosis and the treatment of some of the most  
4 prevalent diseases that we have in the United States. Greater than 90  
5 percent of the total PET studies that are performed using F-18 FDG are  
6 essentially a diagnostic for cancer. Also PET is used to diagnosis  
7 cardiovascular disease, using -- and various disorders, using --13  
8 ammonia, rubidium-82 for perfusion studies, looking at cardiac viability  
9 with FDG. Also brain disorders are clinically evaluated for dementia and  
10 for seizures with FDG.

11 Just a few PET statistics for you all to consider. The number  
12 of cyclotrons licensed currently in the United States in 2005 were 177,  
13 and the number for 200 -- for 2006 has increased to 185. The overall  
14 number of PET scanners in the United States in 2005 was 1280. So a  
15 significant number of PET imaging devices.

16 As far as the projection of the number of PET studies that we  
17 actually perform on an annual basis, in 2000, we were at about 211  
18 thousand PET studies, which in 2005 had increased to over a million  
19 studies, and projected for 2010 to increase to over 2 million studies in  
20 the United States. So we are talking about large numbers of our  
21 population. Probably everyone in this room at some point in their lives

1 ~~will have a relative, a family member, or friend that will have a PET study~~

2 performed.

And I also want to talk a little bit

3 about the advances in PET in terms of the research entity that we are

4 dealing with. There is a tremendous amount of research ongoing in PET

5 in both academic centers and in industry. This research is much greater

6 than current imaging research. Companies such as GE, Bristol-Myers

7 Squibb, Scherring, and Merck, are all involved in developing these PET

8 tracers.

9 I believe, as many others do, that the future of nuclear

10 medicine really is in the hands of PET as a science. So as far as the

11 development is ongoing for cancer diagnosis, there's agents out there

12 looking at cell proliferation, looking at hypoxia, which is essentially the

13 oxygenation of tumors, using fluoromisonidazole, copper ATSM, also

14 monitoring anti-therapy angiogenesis therapy, which is essentially the

15 development of the circulation for the tumors, which is something that,

16 therapeutically, we would like to inhibit. And there are agents in PET

17 used to essentially -- being developed to look at that therapy.

18 Also in terms of the research ongoing in neurological

19 disorders, there Alzheimer's research is at a significant pace. As we

20 reach an aging population Alzheimer's has increased dramatically.

21 Diagnosis is being performed in the research centers for Alzheimer's.

1 ~~Again, they are developing therapies.~~

2           So the hope is that with these agents, PIB and fluoro-  
3 amoroid, that we will be able to diagnosis this disease at an early state  
4 and then institute therapies to essentially prevent the progression of this  
5 debilitating disease. As well, Fluoradopa, another agent that is on the  
6 research horizon, has been used for neuro-endocrine tumor imaging, as  
7 well as for treating or diagnosing Parkinson's and movement disorders.  
8 Also, cardiovascular profusion viability agents are being developed,  
9 fluorine-18 labeled preferably, and that allows us to not just use them at  
10 an institution that has a cyclotron on site, which is the academic research  
11 centers, but these agents are labeled with fluorine-18, 110-minute half  
12 life, allows us to deliver them to the community essentially for  
13 distribution through PET centralized radionuclear pharmacies.

14           Also agents are being developed to monitor therapy, regular  
15 therapies such as chemotherapy, radiation therapy, anti-angiogenesis  
16 therapy. We can do pre/post therapy administrations to observe how  
17 that progress is going. Should we continue it or should we stop? It's not  
18 being effective. So this, again, non-invasively is able to monitor  
19 therapies. Also, the new device, the CT PET device, which essentially  
20 fuses CT, looking at the anatomy, with the PET image that shows us the  
21 metabolic state of these processes, exact locations in the body -- I don't

1 ~~know if you've ever seen this CT PET images, but they are pretty~~

2 phenomenal as far as the information that they allow clinicians.

3 Overall, ACMUI supports the proposed EAct categorization  
4 of accelerators and endorses not regulating the therapy accelerators.

5 ACMUI also supports high compatibility across state lines for mobile PET  
6 licensing, for centralized nuclear pharmacy, again, allowing the flow of  
7 radiopharmaceuticals for patient use and not prohibiting their movement  
8 across State lines.

9 Also, we would like to see standardized training and  
10 experience requirements. Again, this allows trained personnel to be  
11 employed in various States under a single kind of training and  
12 experience requirement.

13 Some of the concerns that ACMUI has voiced – one is just  
14 maintaining the availability of PET radiopharmaceuticals for research  
15 and clinical practice. Both are essential. We are concerned about the  
16 timeframe of these legislations as far as the requirements for particularly  
17 the research group.

18 I have talked with the NRC staff regarding institutions which  
19 are involved in human research, specifically the licensing -- the  
20 legislation talks about cyclotron facilities licensed as pharmacies with the  
21 State or licensed with FDA. We have a cyclotron facility at our institution

1 ~~that is not licensed as a pharmacy. It is not licensed with the FDA. So~~

2 essentially, we are still performing research, clinical research studies.

3           So there is some problem in that -- in talking with the staff,  
4 what they pointed out was that all of these academic research centers  
5 work under the auspices of the radioactive drug research committees in  
6 our institution, the RDRC's. And these, they look at as an arm of the  
7 FDA. So they assured me, and I'm relaying this to the community, that  
8 this is acceptable, that they don't, in fact, have to be licensed as a State  
9 pharmacy or as a -- with the FDA, per se, but that they are acting under  
10 the auspices of the FDA through the RDRC Committee at their institution.

11           Again, another issue of concern was noncommercial  
12 distribution of PET radionuclides for research and development. Again,  
13 the staff has assured me that this is really not a problem. There are  
14 academic institutions that are producing radionuclides for distribution to  
15 other non-medical facilities, other academic situations, institutions, as  
16 well as into the industrial sector. And they said this is covered under the  
17 current Part 32; that we don't need additional legislation to cover these  
18 PET radionuclides for distribution from these centers.

19           Also, another concern was the impact of decommissioning  
20 financial assurance. It does create a special hardship for older facilities.  
21 For example, in our institution, we have two positive ion machines.



1 ~~They're old 16 and 15 MEB machines. And in order to decommission~~

2 these two machines, it will cost our institution a million dollars. And  
3 again, to assure the decommissioning of these machines, it will be an  
4 increase certainly to our financial assurance.

5           Also, there are concerns regarding the 16 MEB cyclotrons,  
6 which are in -- they are above the threshold for neutron activation, so  
7 they will require decommissioning assurance. And again, there are  
8 machines in the commercial sector: the GE's, the IDA's, the Echo  
9 machines, all are the larger 16 machines, roughly, MEB machines used  
10 in centralized PET pharmaceutical production.

11           So again, it's just, as these licenses come into these  
12 regulations -- not that I'm saying they shouldn't face these costs, but the  
13 timeline is an issue in terms of for us at our institution, thinking in terms  
14 of an existing NRC license, that an amendment should be within six  
15 months after February 2007 for submission of the amendment, and then  
16 a year following, possibly, to be in compliance, will be a very difficult if  
17 not impossible task for us.

18           I also know that the NRC staff has discussed the waiver  
19 dates and this is something that, again, has not been clarified, but they  
20 did mention that they will break the non-Agreement States into groups,  
21 and that there will be different waiver dates set for these.

1 ~~Certainly, I ask you to at least consider the non -- the~~  
2 academic sites that, again, are a little bit harder to respond than  
3 commercial sites, as well. They kind of need a different kind of  
4 consideration.

5 I'm sorry. The next slide, please.

6 The aggressive implementation schedule, again, may be  
7 difficult for new NARM licenses, as well as NRC in terms of  
8 accomplishing it, as well as the older facilities -- mobile PET,  
9 freestanding PET facilities as new licenses, and our academic sites as  
10 being the older institutions.

11 Again, license guidance is needed at the publication date of  
12 the rule, which I know you're aware of. But we feel that this should be  
13 vetted license guidance, as previously made available to ACMUI so that  
14 we could at least review that guidance before it is published so that we  
15 could refine and clarify this as far as licensees.

16 Next slide, please.

17 As NRC is moving all RAM under a single umbrella,  
18 essentially similar to State regulation, which they have done for the last  
19 40 years, I just want you to think about the fact that this State  
20 organizational structure has required years to put into place. And  
21 typically the States, when NRC changes regulation, are allowed three

1 ~~years after the effective date to be able to come into compliance. So,~~

2 again, with your own existing NRC licenses, it is something to think

3 about, that these waiver dates could allow us the fullest extension

4 possible. This would at least give us additional time to be able to come

5 into compliance.

And again, in terms of -- I mentioned

6 previously allowing a sufficient time interval for all the States to come

7 into compliance, and I can't stress that to a greater extent.

8 But also, just as an aside, FDA, another Federal agency, has

9 been in the process of regulating -- establishing regulations for FDG for

10 the last 11 years. We still do not have regulations that have been

11 published for the preparation of FDG, though this has been an ongoing,

12 regular discussion for 11 years. They are hoping to publish these

13 regulations this year, and then we will have two years after the effective

14 date to come into compliance.

15 So, again, this is a science, a clinically used process that

16 really does need -- just the thought that it takes time for us to be able to

17 accomplish these tasks and not to essentially suppress the research that

18 is ongoing as the regulatory framework is being put into place.

19 COMMISSIONER MERRIFIELD: Clarification. By your third

20 bullet, you're in the process of FDA. You're not suggesting that we take

21 ten years?

1 ~~DR. SCHWARZ: No, no, not at all.~~

2 COMMISSIONER MERRIFIELD: That is not the model that  
3 this Commission generally accepts.

4 DR. SCHWARZ: No, no, definitely not. Just, all that I'm  
5 saying is, it has been a significant process to try to resolve even one  
6 portion of this regulation. Now we're beginning to discuss regulating our  
7 accelerators and regulating our facilities.

8 Medicare, again, has extended its coverage as of May 8,  
9 2006 to cover all cancers under the new PET registry. And this will,  
10 again, significantly increase the numbers of PET studies, the numbers  
11 that are able to actually have PET studies performed.

12 COMMISSIONER JACZKO: Just to clarify that: You showed  
13 previously a projected increase to 2 million PET --

14 DR. SCHWARZ: Right. This is something that --

15 COMMISSIONER JACZKO: Does that include was --

16 DR. SCHWARZ: I'm not sure that it was included because  
17 that projection was done prior to this being accomplished. It may include  
18 that, but it may not. I have a feeling that it doesn't fully include it.

19 Radium-226 as a discrete source is obsolete for medical  
20 clinical application since 1989, and there are no other discrete sources  
21 that we are aware of similar to radium-226 expected for medical research

1 use.

2 The overall number of radium-226 sources remaining in  
3 inventory is unknown, but it is felt that it is much, much less than the  
4 IAEA Code of Conduct for category 2 sources. Thank you for this time.

5 CHAIRMAN DIAZ: Thank you. Mr. Brown?

6 PRESENTATION BY MR. BROWN

7 MR. BROWN: Thank you. First over all, let me thank the  
8 Commission for the opportunity to come speak with you this morning.  
9 We have been working with NRC staff very closely since last August, so  
10 it is nice to come and speak directly to the Commissioners on this  
11 important issues for the medical community.

12 CORAR, as you know, represents the manufacturers. It is  
13 the North American trade association for the manufacturers of  
14 radiopharmaceuticals, medical radionuclides, and radionuclides used in  
15 research, biomedical and other research. CORAR has also been working  
16 very closely with the American College of Radiology, the American  
17 Association of Physicists in Medicine, and the Society of Nuclear  
18 Medicine.

19 We can skip over the acronyms. They're there for your  
20 reference. If we can go to slide number 3.

21 First of all, some general comments on the NARM

1 ~~rulemaking. We feel the staff has put a tremendous amount of effort into~~  
2 the rulemaking. They have accomplished an incredible amount of work  
3 in a very very short period of time. The staff, both the NRC staff and  
4 some of the Commission's personal staff, has been very, very helpful in  
5 understanding the medical community's needs and working with us to  
6 work to a logical conclusion on this rulemaking.

7           Also, it's fair to say CORAR members are generally pretty  
8 pleased with this rulemaking. For a long time, we have been in favor of  
9 including NARM in the Atomic Energy Act, and we have been very  
10 supportive of this. Frankly, we're pretty pleased with this rulemaking.  
11 We do have some technical comments and some minor fixes that need to  
12 be done during the rulemaking process, however.

13           Next slide.

14           Let me discuss some favorable sections of the draft  
15 rulemaking, as we see them. First of all, the delineation of the three  
16 different types cyclotrons. This was a very, very difficult topic, since the  
17 Atomic Energy Act did not really grant -- or since the EPA Act from last  
18 year did not really grant NRC the authority over cyclotrons, obviously  
19 every time we turn on a cyclotron, to some degree there is some neutron  
20 activation with the higher machines.

21           So NRC staff had a very difficult time in determining how to

1 ~~not include the cyclotrons but include the materials. So we feel they~~  
2 have done a very, very good job and a very appropriate job in dividing  
3 the cyclotrons up into three different categories and regulating two of the  
4 three. We are very pleased with that.

5           Also, we are very pleased with the grandfathering in Part 35,  
6 authorized users and authorized nuclear pharmacists. We feel this will  
7 be very, very helpful to licensees. For example, if we have an authorized  
8 user or an authorized nuclear pharmacist under an Agreement State  
9 now, or even under a non-Agreement State, and they transition to an  
10 NRC license, they can be grandfathered if they've already been doing  
11 that work. If they've been working at a facility for ten years doing that  
12 job, they can grandfather under a new NRC license. So that's something  
13 that will be very, very helpful for licensees in the field.

14           Also, in NRC's waiver they published several months ago, it  
15 will really allow for a very seamless operation. It will allow time to  
16 transition from the old rulemaking structure into the new rulemaking  
17 structure. So the waiver will be very, very helpful.

18           Also, we understand, talking to NRC staff, that they are  
19 planning another workshop once the draft rule is published, and we are  
20 very pleased with that. As I said before, we feel there are some  
21 technical corrections that need to be worked out, and we feel this

1 ~~workshop is a great opportunity to do that.~~

2 Next slide.

3 Let me discuss some concerns with the draft rulemaking.

4 There's been a lot of talk about compatibility level. We are looking at --  
5 Most of our comments dealing with compatibility don't fall back to the  
6 definition of byproduct material. They are on several other parts of the  
7 rule in the compatibility level B.

8 Our concern with the whole compatibility level B issue is,  
9 even though a lot of these regulations are assigned to compatibility level  
10 B, which is a very high level, they're really not being implemented  
11 uniformly across the States.

12 Some examples of this are the sealed source registry. If one  
13 of the CORAR member companies goes out and gets a sealed source, on  
14 the sealed source registry in one State, it is not necessarily recognized  
15 by another State. So even though there may be adequate regulations,  
16 some of the States don't recognize there are other sealed source  
17 registries. Some States don't recognize the NRC's sealed source  
18 registry.

19 So even though some of these have very high levels of  
20 compatibility, it's very difficult for manufacturers that are trying to engage  
21 in interstate commerce to deal with all 50 States when sometimes there



1 ~~are disparate regulations.~~

2 COMMISSIONER MERRIFIELD: Could you repeat that last  
3 comment regarding States not accepting the NRC's registry? Is that  
4 what you said?

5 MR. BROWN: We have specific examples of States not  
6 accepting each other's sealed source registry. I may have misspoken. If  
7 I said that States won't accept NRC, I shouldn't have said that. It's one  
8 State not accepting another State's sealed registry.

9 Also, we feel reciprocity needs to be done between the  
10 States, especially in the case of sealed sources, authorized nuclear  
11 pharmacists, authorized users, and RSO's. We have several examples  
12 where, in one State, someone may have been a practicing RSO in one  
13 State under an Agreement State license, and when the company wants  
14 to move them to a nuclear pharmacy into a different State, all of a  
15 sudden, they are not qualified to be an RSO in that new State.

16 Even though they may have been doing that job five years,  
17 ten years, 15 years, 20 years in another State, that new State may have  
18 requirement to have a bachelor's degree in health physics that the old  
19 State didn't have. So even though that RSO may have been serving in  
20 that capacity in another State, in an identical facility, all of a sudden, he  
21 is not qualified to be an RSO in the new State.

1 ~~Also, we have a need for some specific PET-derived air~~  
2 concentrations DACs in Part 20. NRC was faced with a difficult  
3 challenge because some of the derived air concentrations for some of  
4 the PET nuclides, in particular, oxygen-15 and nitrogen-13, the States  
5 had different DACs, depending on which State you looked at. So rather  
6 than try to resolve that difference, the NRC chose to go with the default  
7 value for O-15 and nitrogen-13 for the DACs. However, that default  
8 value is 15 to 20 times higher than it would be if you calculated a specific  
9 DAC.

10           So this is something we have been talking to NRC Staff with.  
11 CORAR plans on filing a petition for rulemaking, asking NRC to adopt a  
12 specific derived-air concentration for those two radionuclides. It is our  
13 hope that NRC staff and NRC will be able to work that into this  
14 rulemaking so that our petition for rulemaking and this rule can be  
15 finalized at the same time.

16           Next slide.

17           There is also some concern about financial assurance for  
18 decommissioning. As Sally mentioned, there's several cyclotrons out  
19 there, especially the lower energy cyclotrons, specifically less than 11  
20 MeV that are self-shielded. And because they are self-shielded and  
21 because of the low energy of the accelerated particles, they have a

1 ~~tendency not to do neutron activation.~~

2           So consequently, our interpretation is, if you look at Part 30  
3 and you look at the pending C values and look at the 120-day half life,  
4 those facilities will not have to post a decommissioning bond in order to  
5 get their license. So this is something we are going to look for  
6 clarification from NRC staff on. That's our understanding, and that's the  
7 way it's being explained to us. But we will put that in the form of a formal  
8 comment during the rulemaking process.

9           Also, many States recognize some PET cyclotron operators  
10 and some PET engineers as authorized users in their individual States,  
11 which is a good thing. However, there is no provision to grandfather  
12 these into new licenses and into new NRC licenses. So this is something  
13 we would like to see, the grandfathering of cyclotron engineers and  
14 cyclotron operators, grandfathering just like authorized users and  
15 authorized nuclear pharmacists. So, once again, that is a common word  
16 we continue to work with NRC staff on.

17           Next slide, page 7.

18           The last concern we have with the draft rulemaking is on the  
19 new fee structure. We understand NRC's fee recovery process.  
20 However, we feel in some cases, this will be a financial burden for some  
21 licensees.

1 ~~In some particular cases, if a facility, a cyclotron facility in~~  
2 particular, is in a non-Agreement State, right now they may have no  
3 license fee, they may have no registration fee, they may have nothing.  
4 When they transition to a new NRC license, they will have -- they'll go  
5 from paying very low fees or no fees to paying fairly high fees. We  
6 recognize that NRC is kind of backed into a corner on this because of  
7 your fee recovery processes, and maybe there's not a lot you can do  
8 about it. But this will be a financial burden for quite a few small  
9 licensees. Next slide.

10 I have a couple of quick comments about the secure transfer  
11 portion of the EAct. CORAR really feels that radiopharmaceuticals and  
12 medical radionuclide shipments really do not warrant an inclusion under  
13 the secure transfer rulemaking. Looking at Congress' intent, going back  
14 to 2003 when this was being discussed, I'm going to read a small portion  
15 of congressional -- from the report of Congress on this.

16 It says, "The NRC should focus particular attention on  
17 identifying radiopharmaceuticals and other medical materials for  
18 appropriate exemption from the new regulations to assure the  
19 uninterrupted availability of these materials to patients that need them."

20 Talking to NRC staff, we believe it is their intent not to  
21 include radiopharmaceuticals and medical radionuclides in secure

1 ~~transfer, although we have not seen the draft rulemaking yet, we really~~  
2 can't make that determination. So we hope that these materials, these  
3 smaller sources, can be exempt from secure transfer. If it involves IEAA  
4 Code of Conduct cat 1 and cat 2 sources, we feel that is appropriate.  
5 Anything less than that, we feel may be overkill.

6 Slide 10.

7 In summary, thank you once gain for the opportunity to come  
8 present directly to you. CORAR will continue to work closely with NRC  
9 staff on this rulemaking, and we hope we have the opportunity to come  
10 and speak with you again.

11 CHAIRMAN DIAZ: Thank you, Mr. Brown. Commissioner  
12 McGaffigan?

13 COMMISSIONER MCGAFFIGAN: Thank you, Mr. Chairman.  
14 I'll start with you, Pearce. During your discussion of Section 652, you  
15 talked about only limiting 652 to those who have currently increased  
16 controls. Does that include everybody who has cat 1 and 2 materials, or  
17 do you mean by that only those who have common defense and security  
18 controls under NRC order?

19 MR. O'KELLEY: Cat 1 and cat 2; both orders and the  
20 increased controls.

21 COMMISSIONER MCGAFFIGAN: Both?

1                   MR. O'KELLEY: Yes.

2                   COMMISSIONER MCGAFFIGAN: So you are in alignment  
3 with me then. That is a good clarification, because I was worried there  
4 for a second.

5                   On Section 652, one of the things that concerns me is the  
6 pace at which we are getting to it. Arguably, if Congress was thinking  
7 rationally about security, it would have placed far less emphasis on 651  
8 and NARM, because there is no security there -- we issued the export  
9 and import rule for radium-226 by direct final rule last month, and that  
10 took care of the security issue. The rest of it is just very complex.

11                   But in 652, if, God forbid, somebody gets a radionuclide of  
12 concern, cat 1 and 2, a quantity of radium of concern between now and,  
13 say, 2011, and an Agreement State, assuming that we get the rule  
14 finalized in late 2008, and then you guys take three years to implement it  
15 if it is done under public health and safety -- maybe we can do it faster if  
16 it's common defense and security. But you would be -- it would be 2012.  
17 And if somebody steals some cat 2 radionuclides in 2010 and that person  
18 would have been caught, you know, Osama Bin Laden's nephew, if he  
19 had been subjected to a background check, we'll be up testifying before  
20 Congress, at least those of us who may still be here in 2010.

21                   CHAIRMAN DIAZ: Thank you.

1                   ~~COMMISSIONER MCGAFFIGAN: The Chairman will be in~~

2                   the audience smirking, perhaps. But it just frustrates me that we are  
3                   doing this sort of backwards. We should be focused on the stuff that  
4                   really has security nexus first and NARM second. Instead, we're  
5                   focusing on NARM first and Section 652 second.

6                   Is there anything the States could do to do the fingerprinting  
7                   faster, rather than take the normal three years?

8                   MR. O'KELLEY: I can speak for my State, and Jared might.  
9                   But this question hasn't been posed to the other States, so I don't want  
10                  my response to be held against them.

11                  As I use my country boy logic and figure out how we can do  
12                  this, it would be just a modification to increase controls, and we could do  
13                  it just, say, as fast as we did that.

14                  COMMISSIONER MCGAFFIGAN: So you could do it just in a  
15                  few months?

16                  MR. O'KELLEY: Yes. It's a subset. We've already asked  
17                  that these folks ensure the trustworthiness and reliableness of these  
18                  people they're using now. It's just an additional step in ensuring that  
19                  trustworthy and reliableness. I don't see where implementing it would be  
20                  any -- take any longer than we already have. And I'm thinking, probably,  
21                  in some cases this has probably already been done.

1 ~~As far as fingerprints, they may not have gone through the~~  
2 Federal blessing, but from a State perspective, I'm sure that's what some  
3 people did to ensure that, hey, when they come in here, they would say,  
4 how do you ensure this guy's reliability and trustworthiness, and I think,  
5 well, we had his criminal history done, we did the fingerprints, we ran it  
6 through our State police.

7 COMMISSIONER MCGAFFIGAN: That raises the question in  
8 my mind. I wasn't intending to go there. This is always surprising. But it  
9 raises the question in my mind as to whether we could not do Section  
10 652, the spirit of 652, faster. We have the authority now. Is it only rule  
11 and not by order that we can fingerprint under 652? I haven't memorized  
12 the section.

13 But if we could do it by -- if 652 is immediately effective and  
14 we can do it, I don't know -- We are talking about 1400, 1500, 1600  
15 entities nationwide, X percentage NRC, X percentage the States, the  
16 States having a larger percentage. And we are thinking of only doing the  
17 panoramic, the radiators, and the manufacturers and distributors under  
18 656.

19 But if we could do the whole ball of wax under Section 652  
20 faster, I would feel a lot better because, as I say, 652, we asked for that.  
21 We wanted to have this authority to fingerprint key individuals. It isn't



1 ~~everybody. And if you have any thoughts as to what key individuals~~

2 would be at Washington Hospital Center, or Georgetown Medical Center,  
3 or George Washington Hospital, I would be interested. But we might be  
4 able to get it done faster, rather than the schedule we're on, which is a --  
5 652 has been postponed because it does not have a deadline, the last of  
6 the rules.

7 MR. O'KELLEY: The only comment is that, A, again, I didn't  
8 want to speak for all the States, but I do believe -- and somebody correct  
9 me; I'm sure they will -- that when we did the increased controls, we did  
10 get some stakeholder input from the licensees. And I don't know that we  
11 have got that information.

12 I heard the question earlier about how many people are we  
13 talking about. I can see in a large academic research institution, you're  
14 talking about a heck of a lot of people.

15 COMMISSIONER MCGAFFIGAN: Who touch category 2 and  
16 above?

17 MR. O'KELLEY: Well, through -- the potential is there. So  
18 I'd like to say if we are going to go this route, we might want to get some  
19 stakeholder input.

20 COMMISSIONER MCGAFFIGAN: Sure. In a hospital, in a  
21 category 2 at Washington Hospital Center, or GW, or Georgetown tends

1 ~~to be the cesium blood irradiator. And that's the focus. That would be~~  
2 the focus. How many people touch the cesium blood irradiator in a way  
3 that would require background checks, in your opinion, based on the --  
4 either folks at this end of the table.

5 DR. SCHWARZ: I'm not sure how many people. I know that  
6 they are in the process of putting security in place for blood irradiators at  
7 Washington University. But I don't know how people many people are at  
8 the finger --

9 COMMISSIONER MCGAFFIGAN: How many would you -- It  
10 isn't every janitor, presumably, who gets fingerprinted. It's the RSO and  
11 a few other folks.

12 MR. BROWN: And I think you'd say that the number is  
13 higher at your teaching hospitals and research centers.

14 COMMISSIONER MCGAFFIGAN: Okay. George Pangburn  
15 has come to the--

16 MR. PANGBURN: Just anecdotally, I think we can offer that  
17 under most circumstances, the number is probably between five and  
18 fifteen, but a lot of it depends on how many researches are using those  
19 blood irradiators and whether they are being used. As you know, in the  
20 briefing package we provided to you, the scope of use of that one  
21 particular irradiator has scaled down dramatically. So I think that the

1 ~~numbers are going to be all over the map.~~

2 COMMISSIONER MCGAFFIGAN: I'm trying to think of the  
3 total numbers. If it's 1500 times five to fifteen, we are talking a couple  
4 hundred thousand, max, and maybe 100,000 individuals who today don't  
5 have fingerprints and background checks done that we would be  
6 fingerprinting and background checking by some date in the future under  
7 Section 652. Is that doable in a finite period of time? And I will shut up.

8 MR. BROWN: I think it's doable from a regulatory control  
9 program. Whether it's doable for the licensees, whether it's doable for  
10 the law enforcement agencies, and how fast they can get those done,  
11 that's one reason I urge to let's -- you know, I think the law says Federal  
12 background check, to run these through our State police, which would  
13 have the same access, or our State FBI counterparts.

14 COMMISSIONER MCGAFFIGAN: I think that the Federal  
15 background check is in 656. I think, in 652, it shows --

16 MR. BROWN: Criminal history check?

17 COMMISSIONER MCGAFFIGAN: Criminal history check.  
18 And I think that can be done.

19 MR. BROWN: Thank you. Jared might want to --

20 MR. THOMPSON: Just to follow up a little bit, real quickly:  
21 Commissioner McGaffigan, the numbers will change. Whatever set you

1 ~~do today, a month from now it will be different because of just the way~~  
2 the turnover is, the research aspects of it.

3 And Pearce is right: Increased controls has opened the door  
4 for us to -- we can do a little bit better, get that in place a little bit faster.

5  
6 CHAIRMAN DIAZ: Commissioner Merrifield.

7 COMMISSIONER MERRIFIELD: Thank you, Mr. Chairman. I  
8 want to turn back to the accelerator-produced material, 651(e). I was  
9 listening to Pearce, your comments about the definitions. Remembering  
10 back to my legal training, where there is a tendency in statutory  
11 construction where folks will sort of pass over the definitions and get  
12 right to the implementing language. And the lawyers will always tell you,  
13 really you're going to spend most of the time on the definitions because  
14 that's really where it all stems from.

15 I guess I'm trying to understand -- I read all the comments  
16 from the States, and I see the number of the folks who think that D is the  
17 right way to go. And the heart of the concern, as you've articulated it  
18 today, is a concern that you have to go back and make a statutory  
19 change in order to effectuate that.

20 You're further saying that under the way in which you've  
21 implemented over years, you are using the more encompassing term of

1 ~~radioactive material, and we're asking you to do a subset of that, which is~~  
2 byproduct material.

3           And I guess what I'm trying to understand is, if the State  
4 statutory authority is based on the notion of radioactive material, and  
5 that's where you are getting your authority to regulate, I guess I don't  
6 understand why that is -- because it is a broad umbrella provision, why  
7 the regulatory bodies in the State don't have the authority to construct  
8 regulatory changes under that more broad umbrella and why you feel you  
9 have to go back and get a more specific legislative change?

10           MR. O'KELLEY: We do have the authority under our  
11 umbrella. To get into change was being required by the NRC and the  
12 way they were initially defining category C. Please, if you take one thing  
13 out of here, take -- The reason everybody said D was because of the way  
14 somebody mischaracterized C. And if that was the way that compatibility  
15 C was going to be implemented, then we couldn't say yes, we will go with  
16 category C.

17           We can do it. We can do it. If NRC tells us we have to have  
18 a verbatim definition from the beginning of the sentence to the period  
19 exactly like NRC's -- and that was what is coming out initially -- and that's  
20 why you saw the States get up in arms, because we do have the  
21 authority under our State statute to regulate this now. We have been

1 ~~doing it for years. The issue is whether NRC is going to require us to~~  
2 have the same words written down in our statute and our regulations just  
3 because somebody says it's got to be exactly the same. But we are  
4 going to regulate it the same. We regulate every radioactive material the  
5 same now as we do with the rest of the byproduct material. That's not  
6 going to change. Actually, that's just what we call it.

7 MR. THOMPSON: Perhaps, also, you used the word "have  
8 to." We do not know how many States will -- may be necessary. We  
9 know that 27 have it in statute, but we do not know how many of them  
10 will have to make changes.

11 COMMISSIONER MERRIFIELD: Well, we've got Mr. Brown  
12 on this side of the table who would like to go from C to B or B plus, or  
13 whatever.

14 MR. O'KELLEY: I think he was talking about a different  
15 issue, I hope.

16 COMMISSIONER MERRIFIELD: I may be confused here. I'm  
17 sorry.

18 MR. BROWN: But the definition of byproduct, we are not as  
19 hung up on that as we are all the other things. We would love to see  
20 everything across the board at compatibility level A, but that's a different  
21 issue. But I guess where we have a problem is, we are trying to do

1 ~~business in all 50 States, and in many cases each State is different, and~~  
2 all the States change, and customers call us and say, well, what does the  
3 State of Kentucky require this week? We say, we're not sure; we'll have  
4 to double-check. And this is very hard when the States handle different  
5 parts of the regulations differently.

6 And they are very -- Within the State, it's fine, but when you  
7 try to do business interstate, it's very difficult sometimes.

8 COMMISSIONER MERRIFIELD: Relating back to your  
9 comment there about attempting to get more involved -- Well, no, I'm  
10 going to back away from that one -- Well, I may have to go back and  
11 take look at that. I'm still struggling with -- Apparently, there were some  
12 comments made by our staff that got you all worked up about this;  
13 perhaps more than we had intended, and I'm going to have to go back  
14 and take a look at how that all comes together.

15 MR. O'KELLEY: From a State perspective, the issue is, just  
16 don't make us jump through hoops we don't need to jump through when  
17 we've already got it covered.

18 Just a comment: I think you will you find with this that the  
19 States will be regulating this the same way we are doing the other  
20 medical byproduct materials currently. So I think a lot of your concerns --  
21 I understand the SS&D issue, and I that's kind of happened in one case

1 when people were trying to kind of push CRCPD's licensing state for

2 NARM. But I don't think it's going to be –

3 CHAIRMAN DIAZ: I think I'm doing to have to interrupt you  
4 because this is a subject for a leisure afternoon someplace doing  
5 something else. Dr. Miller?

6 COMMISSIONER MERRIFIELD: Charlie, you want to --

7 PRESENTATION BY DR. MILLER

8 DR. MILLER: Thank you. I'm Charlie Miller from NMSS.  
9 Thank you, Mr. Chairman.

10 One of the things that I wanted to make clear so that the  
11 Commission is clear is, I think the States -- as you can see, this issue on  
12 compatibility has caused a lot of emotion, and not all stakeholders agree  
13 on where we ought to be. What you see experienced and lived out was  
14 the fact that in this rulemaking effort, the staff has probably engaged the  
15 States and other stakeholders more than we ever have in my experience  
16 in other rulemakings. And what you saw were, the compatibility C was  
17 brought out as staff thinking at time.

18 We had a short timeframe to try to frame something. As we  
19 framed something, we shared it through our Working Groups and  
20 Steering Committees, and the compatibility C issue brought a lot of  
21 interest and a lot of emotion to the table. And all the discussions that we



1 ~~had subsequent to that allowed us to do further thinking. And you heard~~  
2 Kathleen Schneider eloquently outline how we came out to health and  
3 safety.

4           So in the end, we didn't go with compatibility C; we went with  
5 health and safety because we recognized that we felt that that was where  
6 we could go to give the States the maximum flexibility, but yet  
7 compatibility D, we felt, just didn't do what we needed to have done.

8           So in the end – and I hate to use the term “it was sausage in  
9 the making,” but that’s kind of what rulemaking is. We debate it back  
10 and forth, we exchange ideas, and then we try to come up with the best  
11 proposal we can for the Commission.

12           CHAIRMAN DIAZ: Thank you, Charlie.

13           COMMISSIONER MERRIFIELD: Mr. Chairman, just a last  
14 comment on here. I understand – and, Charlie, thank you for the  
15 clarification. I understand the back and forth, and I know that the States  
16 are coming from, here we’ve been regulating this for four years.

17           I would say, as a personal view -- and I appreciate the fact  
18 that the States have been doing this. I think what Congress decided to  
19 fill was a gap in the Atomic Energy Act. If we could turn time back, we  
20 should have been involved in this thing a long time ago. But it is what it  
21 is. Congress has given us the marching orders to get involved in this

1 ~~area, and we are just going to have to take it from there.~~

2 CHAIRMAN DIAZ: Thank you. Commissioner Jaczko?

3 COMMISSIONER JACZKO: I want to focus a little bit on  
4 some of the points that you raised, Dr. Schwarz, particularly if you could  
5 talk a little more about the mobile PET licenses. And you mentioned that  
6 that was an area where there was some particular concern with  
7 compatibility across State lines. If you could perhaps just describe what  
8 those machines are and what kind of communities they serve, what kinds  
9 of functions they fill, and what some of the issues are that you're  
10 concerned about.

11 DR. SCHWARZ: Again, the mobile PET is actually a camera  
12 on a truck. And it essentially moves between institutions. So it provides  
13 the ability to have these PET scans performed at different places, and  
14 some of them, across State lines. So this is just a concern that we're  
15 able to deal with having these devices not have problems working in two  
16 different States, providing radiopharmaceuticals for these types of  
17 situations.

18 COMMISSIONER JACZKO: Are there any specific areas  
19 where you have some concern that there may be a problem moving from  
20 State to State with these kind of -- or is it just right now, on a --

21 DR. SCHWARZ: It is just a general statement; no, not a

1 specific.

2 COMMISSIONER JACZKO: Okay. Thank you. This is  
3 something I asked the staff, and perhaps this is a question for Mr.  
4 O'Kelley, or Mr. Thompson, I think you wanted to answer this. I asked  
5 about radium-226 and our approach to dealing with radium-226.

6 Perhaps you may have some more experience or greater  
7 access to some information on what the status is of some of the  
8 consumer products that are out there and what approaches should be  
9 taken to deal with these -- either generally licensing them or exemptions.

10  
11 MR. THOMPSON: I can speak for my State. We know about  
12 where some of the antiquity stuff might be, but to say we have a handle  
13 on all of it would be near about impossible to say. You see this stuff  
14 popping up on eBay, whether it be watch dials, aircraft dials. It comes  
15 up any time. We find them in scrap yards all the time.

16 I don't know that you could put a number on them. And  
17 there's lots of dealers out there. These guys -- And I will give you for  
18 instance. Back about are eight or nine years ago, in Arkansas, we had a  
19 scrap dealer who had a 30-gallon drum full of dials, radium dials. And  
20 I'm not going to tell you -- Then we went back to a non-Agreement State.  
21 We don't know what happened to it after that. So they float out there.

1 They just float around. It's hard to get a handle on just how many of  
2 them are out there, where they're at, and who might have them.

3 COMMISSIONER JACZKO: How do you handle them?

4 MR. THOMPSON: When we find them, we get them properly  
5 disposed of. That's the only method we have to deal with anything that's  
6 below a level of an exempt source that's in the SSR's.

7 COMMISSIONER JACZKO: Are they considered an exempt  
8 source, then, in your State?

9 MR. THOMPSON: We just try to route them to be disposed  
10 of.

11 MR. O'KELLEY: They are not exempt sources. They're not  
12 necessarily licensed since nobody, as Jared said, knows where they are.  
13 We found some the other day. Somebody called and told us. A  
14 gentleman upstate was selling radium paint on eBay. Every time  
15 somebody goes and buys an old farmhouse, in the barn, and there is no  
16 telling what they find in the backs of those things. You know, watch dials  
17 and so forth.

18 I think that it's probably a good direction to maybe look at it more  
19 from a risk-based standpoint, if we can put some numbers on them,  
20 whether these are risks that need to be regulated or are these risks that  
21 do not. I think it is going to ask somebody to do some additional

1 research.

2 I think, generally, licensing these is an exercise in futility  
3 almost because you don't know where they. You can't get in touch with  
4 them. And they're not going –

5 COMMISSIONER JACZKO: Apparently, they are on eBay.

6 MR. O'KELLEY: They do show up from time the time on  
7 eBay, as well as Night Vision goggles and other things that are out there.

8  
9 COMMISSIONER JACZKO: I appreciate that. As I said I do  
10 appreciate what the staff is doing to try and handle this, but to some  
11 extent, there may not be a lot of practical difference between handling it  
12 as a general license or going the route of exemption. But I'm interested  
13 in hearing more from the staff on that. Those were the – I did have one  
14 other question.

15 This is the issue, Mr. Thompson, you brought up about --  
16 dealing in particular with Section 656 and the Federal background check  
17 requirement. You talked about working through the State database, or  
18 through the State law enforcement agencies. Do they then process that  
19 through the FBI, or do they perform their own background check?

20 MR. THOMPSON: Mr. O'Kelley.

21 COMMISSIONER JACZKO: Oh, I'm sorry.

1 ~~MR. O'KELLEY: Trish always corrects me on this, but I think~~  
2 one of the ladies that was with the FBI on the Energy Task Force did say  
3 that that information was available to the States, and the States use that  
4 database? Correct me again.

5 COMMISSIONER JACZKO: Perhaps, Trish, you can clarify  
6 this then so that -- I guess the point I'm trying to get at is, a background  
7 check that is done that way is effectively going through the Federal  
8 database or the Federal system?

9 MS. HOLAHAN: Yes, that's correct. This is Trish Holahan.  
10 I'm with NMSS.

11 The FBI person on the Energy Policy -- the Chairman's Task  
12 Force said that if they got it to -- the State police had access to the FBI  
13 watch list. So it is a Federal check, but you can get it through the State  
14 police.

15 COMMISSIONER JACZKO: The State police. I don't know if  
16 the staff has looked at that. Maybe, Karen, you can answer this one. Is  
17 that consistent with the language that says Federal security check, or  
18 would it actually have to go through the Federal --

19 MS. CYR: I think we looked it. I think that meets the -- at  
20 least our preliminary look at that meets the understanding or the intent of  
21 the statute on doing a background check.

1                   COMMISSIONER JACZKO: Thank you.

2                   CHAIRMAN DIAZ: Thank you. Commissioner Lyons?

3                   COMMISSIONER LYONS: Pearce O'Kelley mentioned that  
4 last week in Detroit -- I happened to be here to hear some of the  
5 discussions from a number of the State representatives with their  
6 concerns on obtaining the Governor certifications. Certainly, as you  
7 said, I did hear some very -- at least, stated to be very substantial  
8 concerns.

9                   I have to admit, though, that I went away thinking that  
10 perhaps some people were trying to make mountains out of molehills and  
11 that it just didn't strike me as nearly as hard as what was being portrayed  
12 by some of the speakers. So I actually went away quite optimistic from  
13 that discussion.

14                  I guess the only question I have -- and I don't know if it for  
15 Mr. Brown, or Ms. Schwarz, or maybe a combination of both of you.

16                  But, Ms. Schwarz, you mentioned complications with mobile  
17 PET facilities that cross State lines. Mr. Brown, among other things, you  
18 mentioned concerns with distribution of radiopharmaceuticals to different  
19 States that have somewhat different interpretations of the rules.

20                  I guess what I'm wondering: Are there cases now where, for  
21 example, States are not able to bring PET facilities across the State line

1 ~~so that there are areas of the country that are not receiving the benefits~~  
2 of the PET scans? Or, from Mr. Brown's standpoint, are there States  
3 where the differences between State regulations are sufficiently onerous  
4 that R&D is being precluded in some States?

5 I'm just trying to get a better handle on how much of a  
6 concern, perhaps, we should have on these State-to-State differences,  
7 or whether the community has found ways to work around, effectively,  
8 whatever differences currently exist?

9 MR. BROWN: I can give you a good example of a  
10 distribution problem. And this is a real-life situation that happened a few  
11 years ago, and it was one of the last NARM radiopharmaceuticals to be  
12 approved. This NARM radiopharmaceutical was approved by the FDA in  
13 an NRC State. The State where it was approved, the State where it was  
14 being manufactured, was not an Agreement State; it was an NRC State.  
15 So, consequently, it did not have a NARM license for this product. So  
16 that the manufacturer in this non-Agreement State tried to distribute it to  
17 all 50 States and went State by State and said, okay, what do you need  
18 in your State, what do you need in your State? Some States said, as  
19 long as it is FDA approved, bring it in, we don't have a problem it. A  
20 couple of States said, well, you have to have some State approve it, from  
21 a radiological standpoint.



1 ~~So the company went to their local State and said, will you~~  
2 review it and approve it, and the State said no, we won't do that. The  
3 company went back to the States that would not accept it, and they said,  
4 well, what you need, then, is a State that is touching the State from  
5 where it's being manufactured to review it and approve it.

6 So the company went to the four States that were touching  
7 the States where it was being manufactured, and now the States said,  
8 no, we won't do it, but one of the States said, if you get another State to  
9 review it first, we will review their review, and then we'll review it, and  
10 then you can get your approval in the State where you want to  
11 manufacture it. Then you can distribute it to all 50 states.

12 That whole process took about ten or 11 months. So it was a  
13 case where this new diagnostic radiopharmaceutical, which was a very  
14 good and effective radiopharmaceutical, was used immediately in  
15 probable 30 States, and in maybe another ten States, it was used within  
16 three months, and then the last two or three States, it took close to a  
17 year to get it into those States.

18 So that is the sort of problem we have with the current  
19 system that is supposed to be compatible. NRC staff has pointed out  
20 that 32.72 now is a compatibility level B. What that means now is that a  
21 new NARM radiopharmaceutical, if one were to come out, it would be

1 ~~clearly a compatibility level B situation. So I'm hoping from that, what~~  
2 would happen with a new non-radiopharmaceutical, it would be  
3 compatibility level B. So once the FDA approved it and the NRC  
4 approved it, in the same example, then all 50 States would accept it. But  
5 that is not clear to me that would happen.

6 DR. SCHWARZ: I just wanted to mention, in terms of FTG, it  
7 is not an approved drug, so again the indications are approved. So that  
8 makes the licensing of this particular entity a little different in terms of  
9 previous radiopharmaceuticals, as well.

10 So coming from misery, we are a non-Agreement State and  
11 really non-robust regulation within our State generally. So it's curious to  
12 me as to how things will proceed. We are not quite sure. We really have  
13 not had State regulation, and we have had NRC oversight for our  
14 byproduct materials. But this is a new world that we step into. And in  
15 the case of many of the non-Agreement States, not many, but certainly  
16 there are others similar to Missouri. So we are just concerned about,  
17 what does this mean as we step forward?

18 COMMISSIONER LYONS: But in the case of the non-  
19 Agreement States, I would have thought, if anything, moving into the new  
20 regime would simplify.

21 DR. SCHWARZ: Well, additional regulation does not ever

1 necessarily simplify things.

2 (Laughter.)

3 COMMISSIONER MERRIFIELD: We try.

4 (Laughter.)

5 DR. SCHWARZ: Thank you.

6 COMMISSIONER MERRIFIELD: That was understated.

7 CHAIRMAN DIAZ: I think I need a drink.

8 (Laughter.)

9 CHAIRMAN DIAZ: Let me start with a little comment. This is  
10 the second time today that I used this phrase: be careful what you ask  
11 for, you might get it. And that's why we are going through these pains  
12 right now. I do believe that the intent of the Commission, when we ask  
13 for something, is clear, and now I guess we will have to come to the  
14 realization that we have to exercise what the Congress has given us as  
15 an obligation.

16 Let me just come to another point. It is highly probable, if  
17 not most probable, that it will be the last time that I address the  
18 Agreement States and CRCPD in my present position, so I want to make  
19 the best of it. And I don't have time to ask a question. I have to ask my  
20 fellow Commissioners to meet me in seven minutes upstairs, if they can  
21 do that, or by 15 to 4:00.

1                   ~~So I'm going to finish my engagement with you with~~  
2 something that I think has been alluded to and is in everybody's mind.  
3 But I think we need to come to grips for. In all of my ten years in the  
4 Commission, we're always dealing with the State issues, as we should. I  
5 am very pro-federalism. I think I have shown time after time that that is  
6 the right way to go.

7                   The Commission has been working with issues back and  
8 forth. We take different positions. Sometimes we go forward, and  
9 sometimes we go back. But eventually there is an issue that remains is  
10 that, for this great country of ours, is very important: that certain things  
11 be treated with a consistent national approach. And you have one of  
12 those issues in your hands.

13                   I think it will benefit this country, instead of arguing about the  
14 legislation to eventually receive recommendations from the Organization  
15 of Agreement States, and CRCPD, and ACMUI, and CORAR on how we  
16 can better ensure a realistic -- because it's not going be perfect --  
17 realistic consistency of dealing with radiopharmaceuticals and other  
18 substances that have to cross borders in this country.

19                   We keep going from viewpoint to viewpoint. But you guys  
20 have to handle it. So I'm going to ask you personally to send a letter to  
21 the Commission with your views on, how can you get a better consistent

1 ~~national approach on the handling of radiopharmaceuticals, radioactive~~  
2 substances and byproduct materials, because I think it is important that  
3 we hear unabashed and totally free from everything, so that you would  
4 do that better, and to better serve the people of this country.

5 And with that, we are adjourned.

6 (Whereupon, at 3:45 p.m., the meeting was adjourned.)  
7  
8  
9  
10